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ABSTRACT
The purpose of this study was to design, synthesize and develop novel transporter
targeting agents for image-guided therapy and drug delivery. Two novel agents, N4-guanine
(N4amG) and glycopeptide (GP) were synthesized for tumor cell proliferation assessment
and cancer theranostic platform, respectively. N4amG and GP were synthesized and
radiolabeled with 99mTc and 68Ga. The chemical and radiochemical purities as well as
radiochemical stabilities of radiolabeled N4amG and GP were tested. In vitro stability
assessment showed both 99mTc-N4amG and 99mTc-GP were stable up to 6 hours, whereas
68

Ga-GP was stable up to 2 hours. Cell culture studies confirmed radiolabeled N4amG and

GP could penetrate the cell membrane through nucleoside transporters and amino acid
transporters, respectively. Up to 40% of intracellular 99mTc-N4amG and 99mTc-GP was
found within cell nucleus following 2 hours of incubation. Flow cytometry analysis revealed
99m

Tc-N4amG was a cell cycle S phase-specific agent. There was a significant difference of

the uptake of 99mTc-GP between pre- and post- paclitaxel-treated cells, which suggests that
99m

Tc-GP may be useful in chemotherapy treatment monitoring. Moreover, radiolabeled
vii

N4amG and GP were tested in vivo using tumor-bearing animal models. 99mTc-N4amG
showed an increase in tumor-to-muscle count density ratios up to 5 at 4 hour imaging. Both
99m

Tc-labeled agents showed decreased tumor uptake after paclitaxel treatment.

Immunohistochemistry analysis demonstrated that the uptake of 99mTc-N4amG was
correlated with Ki-67 expression. Both 99mTc-N4amG and 99mTc-GP could differentiate
between tumor and inflammation in animal studies. Furthermore, 68Ga-GP was compared to
18

F-FDG in rabbit PET imaging studies. 68Ga-GP had lower tumor standardized uptake

values (SUV), but similar uptake dynamics, and different biodistribution compared with 18FFDG. Finally, to demonstrate that GP can be a potential drug carrier for cancer theranostics,
several drugs, including doxorubicin, were selected to be conjugated to GP. Imaging studies
demonstrated that tumor uptake of GP-drug conjugates was increased as a function of time.
GP-doxorubicin (GP-DOX) showed a slow-release pattern in in vitro cytotoxicity assay and
exhibited anti-cancer efficacy with reduced toxicity in in vivo tumor growth delay study. In
conclusion, both N4amG and GP are transporter-based targeting agents. Radiolabeled
N4amG can be used for tumor cell proliferation assessment. GP is a potential agent for
image-guided therapy and drug delivery.
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CHAPTER 1: INTRODUCTION AND BACKGROUND

1

1.1. Functional Imaging in Oncology
There are over 10 million people diagnosed with cancer and over 6 million people
died from cancer every year worldwide. The adaptation nature and heterogeneity of cancer
is one of the main reasons that cancer treatment is challenging. To address this challenge,
functional imaging technologies play important role in personalized cancer medicine [1].
Anatomical imaging modalities, such as computed tomography (CT) and magnetic
resonance imaging (MRI), provide structural detail whereas functional imaging modalities,
such as positron emission tomography (PET) and single photon emission computed
tomography (SPECT), provide insight into biological information [2, 3].
Functional/biological information from the biodistribution of radiolabeled imaging tracers
can be obtained by using functional nuclear imaging modalities. The utility of nuclear
images depend largely on the chemical, pharmacokinetic and pharmacodynamic properties
of imaging tracers. Hence, molecular imaging research is currently focused on developing
new radiotracers for both PET and SPECT technologies [4].

Currently, 2-[fluorine-18] fluoro-2-deoxy-D-glucose, or more informally as 18Ffluorodeoxyglucose (18F-FDG) is the most frequently used PET agent in oncology [5]. 18FFDG was first used as a tumor biomarker in 1980 [6]. 18F-FDG is transported into the cell
through glucose transporter 1 (GLUT 1). It accumulates in cells with high glycolytic
metabolism. 18F-FDG PET provides a noninvasive detection of abnormal activities in
malignant neoplastic diseases.

2

By far, 18F-FDG PET has unmatched clinical utility compared to other functional
imaging modalities [7]. 18F-FDG PET is widely used in many oncology clinical practices in
diagnosis, treatment planning, monitoring of treatment response, and recurrence follow-up
[2, 8-14]. It has been reported that 18F-FDG PET showed high clinical effectiveness in
staging or restaging of Hodgkin’s lymphoma, non-small-cell lung carcinoma and staging
colorectal carcinoma [15]. In addition, hybrid PET and CT equipment improved the
accuracy of 18F-FDG by an average of 10–15% compared with 18F-FDG PET alone [16].
Recent studies demonstrated that 18F-FDG PET/CT benefits patients with lymphomas,
melanomas, cancers in head and neck, lung, breast as well as tumors of unknown primary
origin [14, 16].

Despite wide clinical applications, 18F-FDG PET has certain limitations. Although
18

F-FDG demonstrates high uptake on malignant tissue, it is not specific for tumor cells.

Uptake of 18F-FDG into highly glycolytic areas including sites of infection and/or
inflammation may generate false positive results. Normal tissues, including brown fat,
bladder, muscle, brain and intestines also show high 18F-FDG uptake [17]. In addition, in
those tumors with low glucose uptake, low grade and small size (less than 1 cm), 18F-FDG
shows low sensitivity [5]. Furthermore, in bladder and kidneys, due to high 18F-FDG
excretion, malignant lesions are masked by the high background activity. These drawbacks
not only illustrate the non-specificity nature of 18F-FDG but also limit the application of 18FFDG in oncology. An alternative way to avoid these limitations is to target cell proliferation
using nucleoside analogues.

3

1.2. Imaging Cell Proliferation
All cancers begin in cells. When a normal cell begins to transform, characters and
abilities are changing. During this normal to cancer transformation, certain capacities are
acquired. These capacities include self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis and
tissue invasive & metastasis [18]. Of these six cancer hallmarks, four of them are cell
survival- and proliferation-related. Therefore, un-controlled cell proliferation should be
considered the most important characteristic of cancer cell.

Numerous attempts have been made by researchers to develop specific imaging
probes for tumor proliferation assessment. It is known that the uptake of 18F-FDG generally
correlates with cell proliferation in vitro and in vivo [19, 20]. Studies conducted by different
groups demonstrated that radiolabeled amino acids and their analogues may have similar
potential in cell proliferation assessment [21, 22]. Without a doubt, sugars (such as 18FFDG) and amino acids play important roles in cell proliferation; nevertheless, nucleosides
are the key elements to assess cell proliferation. When a cell proliferates, its DNA must be
duplicated. Since nucleosides are the required elements in the production of nucleotides,
which are essential in building DNA, the uptake and consumption of nucleosides must be
significantly greater in proliferating cells than in resting cells. We may, therefore,
reasonably conclude that radiolabeled nucleoside analogues are the ideal tumor cell
proliferative marker candidates.
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1.3. 18F-FLT as a Cell Proliferation Marker
Design and development of radiolabeled nucleoside analogues which are involved in
DNA synthesis or incorporated into DNA has been reported by various laboratories [23-27].
These probes may be used to assess cell proliferation. For example, 3'-deoxy-3'-18Ffluorothymidine (18F-FLT) is a clinically-tested imaging probe. Many studies have been
performed by various groups to compare the sensitivity and specificity of 18F-FDG and 18FFLT in different tumor types. For example, in glioma, 18F-FLT shows greater sensitivity than
18

F-FDG with higher correlation to proliferation marker, Ki-67 [28]. Treatment response

assessment is another research hotspot of 18F-FLT. The following are few random examples:
18

F-FLT can be used to define proliferation of tumor treated with cytostatic kinase inhibitor

[29], predict survival rate of patient with glioma after bevacizumab and irinotecan treatment
[30], and evaluate dose scheduling [31]. It is worthy to mention that some clinical data
showed there was a low or even no correlation between 18F-FLT tumor uptake and
proliferation markers [32-35]. The cellular uptake of 18F-FLT is mediated by human
nucleoside transporters (hNTs) [36, 37]. The intracellular 18F-FLT will then be
phosphorylated by a cellular kinase known as thymidine kinase type 1 (TK1) [38]. The
phosphorylated 18F-FLT may participate in the DNA synthesis.

Although there is fairly general agreement that 18F-FLT images cellular proliferation
by mimicking a nucleotide involved in the DNA synthesis process, DNA incorporation of
18

F-FLT is low [38]. In addition, the chemistry of making 18F-FLT is complex [23, 24]; as a

result, the radiochemical yield of 18F-FLT is poor. Furthermore, 18F is a cyclotron produced
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isotope. It can only be obtained from cyclotron, so that the price is high and not everywhere
available. All of these pitfalls limit the clinical applications of 18F-FLT [39].

1.4. Advantages of Using Chelation Chemistry and Generator-produced Isotopes
To overcome the inconvenience and high cost of 18F and the poor radiochemical
yield and complex synthetic chemistry of 18F-FLT, generator-produced isotopes plus
chelation chemistry can be used to develop a novel radiolabeled nucleoside analogue for
tumor proliferation assessment. Using chelation chemistry, radioisotopes can be labeled to a
homing agent through a bifunctional chelator. In other words, a chelator should be
chemically conjugated to a tumor targeting homing agent with a covalent bond to form a
single homing agent-chelator conjugate. This non-radioactive cold compound is known as
drug substance. This cold drug substance can be labeled with radioisotope to form the
radiolabeled drug product before use for imaging.

Using chelation chemistry, single homing agent-chelator conjugate can be labeled
with various radioisotopes for different purposes. For example, single drug substance can be
labeled with 99mTc or 68Ga to form two different drug products for SPECT or PET imaging,
respectively. Another example is an 188Re-labeled drug product can be used for internal
radionuclide therapy. 99mTc is preferred to label imaging probes among other radioisotopes
because it has favorable low energy (140 keV vs. 511 keV for 18F), favorable radiochemical
half-life (6.01 hours vs. 109.8 minutes for 18F), inexpensive isotope cost ($0.21/ mCi vs.
$30-50/ mCi for 18F) and capacity for kit product manufacturing. 18F-labeled radiotracers
6

have to be synthesized near the site with a cyclotron and delivered from the manufacturing
site to the hospital shortly before administration due to the cyclotron-producing property and
relatively short half-life. The cold drug substance kit product, on the other hand, can be
stored in the hospital. Once needed, drug product can be produced onsite by adding
radioisotopes generated from an in-house generator. Many 99mTc-chelating techniques and
chelators have been established. Cyclam (N4), DTPA, DOTA, sulfur colloid and N2S2 have
all been reported as being easily labeled with 99mTc with high radiochemical purities and
yields [40-46]. N4 was chosen for the proposed study due to its higher lipophilicity. The
relatively higher lipophilicity allows drug product to more easily penetrate the cell
membrane, leading to greater cellular uptake, decreased kidney accumulation and, as a
result, reducing renal toxicity. Besides, N4 has a closed-ring structure, which is more rigid
and stabilizes the radioisotopes.

1.5. Nucleoside Analogues and Lead Compound Selection
Nucleosides consist of three elements: 1. the heterocyclic based moiety, which is
usually a purine, pyrimidine or their derivatives. Heterocyclic bases play the key role in the
recognition process of nucleosides through forming specific hydrogen bonds with other
nucleosides or proteins. 2. The hydroxymethyl group, which is essential for the
phosphorylation of the molecule by cellular kinases. The phosphorylated nucleotide will
then be recognized by cellular proteins to achieve biological activity. 3. The ribose ring,
which acts like a spacer between the other two elements to keep the heterocyclic base and
the hydroxymethyl group in the correct orientation and configuration. Plenty of nucleoside
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analogues have been synthesized and discovered. Many have been approved with promising
anticancer and antiviral abilities. Among them, some have been successfully developed as
therapeutic agents in both anticancer and antiviral medicine[47].

Anticancer nucleoside analogues include purine-based nucleoside analogues and
pyrimidine-based nucleoside analogues. Purine-based anticancer nucleoside analogues, such
as nelarabine, deoxycoformycin, cladribine, fludarabine, and clofarabine, are mostly
deoxyadenosine analogues. The only exception is nelarabine, which is a deoxyguanosine
analogue. All pyrimidine-based nucleoside analogues used currently in clinical anticancer
treatment are deoxycytidine analogues, including cytarabine, gemcitabine and
decitabine[48]. The primary mechanism of action of these nucleoside anticancer agents is to
inhibit DNA replication and DNA repair. DNA polymerase and ribonucleotide reductase
(RNR) are the two major cellular targets for these agents. Take gemcitabine as an example,
gemcitabine can penetrate cell membrane through nucleoside transporters (NTs). It is
phosphorylated by cellular deoxycytidine kinase to form gemcitabine monophosphate. After
this rate-limiting step, gemcitabine monophosphate can be further phosphorylated to form
gemcitabine diphosphate and triphosphate, which are two active metabolites. Gemcitabine
triphosphate inhibits DNA polymerase and it can also be incorporated into DNA to inhibit
DNA replication and repair. Gemcitabine diphosphate inhibits RNR to decrease cellular
concentration of dCTP. Cellular uptake of gemcitabine is increased to compensate the low
concentration of dCTP [49]. Through this self-potentiation process, gemcitabine becomes a
very potent drug to treat many cancers.
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Antiviral agents, such as acyclovir, penciclovir and ganciclovir [50] (for HSV
treatment), and AZT[51] (for HIV treatment), have several features in common. For
instance, most of them do not have the 3′ hydroxyl groups. Different modifications on the
base moiety and ribose ring are present. However, it has been found that modifications made
on ribose ring of nucleoside analogues sometimes causes chemical instability and clinical
toxicity [25]. To overcoming this drawback, several studies have been directed replacing the
ribose ring by a different five-membered ring system including carbocycles. Examples of
this new generation compounds are carbovir [52], lobucavir [53], and lamivudine [47].
Among them, lamivudine has been proven for the treatment of both HIV and HBV. Similar
to anticancer nucleoside analogues, the mechanism of action of antiviral agents is to inhibit
viral DNA replication. For example, after being transported inside the cell, penciclovir can
be phosphorylated by either viral thymidine kinase or cellular deoxyguanosine kinase [54].
Phosphorylated penciclovir is trapped inside cell and will interrupt viral DNA synthesis to
stop virus proliferation.

N4amG was designed and synthesized using penciclovir as a lead compound. The
advantages of choosing penciclovir were: 1. Penciclovir is known as a guanosine analogue
with high affinity to hNTs. It can be effectively transported into cell through hNTs [54]. In
other words, penciclovir works as an agonist in human body because it preserves the core
guanine structure, and guanine is one of the main nucleobases in human body. 2. In addition
to the core guanine structure, penciclovir has a carbon chain with two hydroxyl groups
instead of a deoxyribose. The carbon chain makes penciclovir resistant to metabolizing
enzymes. By this design, penciclovir obtains longer biological half-life and circulation time
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in human body. 3. The two hydroxyl groups are crucial for pharmacodynamics, especially in
molecular imaging applications. The hydroxyl groups of penciclovir are phosphorylated by
cellular deoxyguanosine kinase as soon as penciclovir is transported inside the cell through
hNTs [54]. Phosphorylated penciclovir is trapped inside cell due to the chemical structure
change and charging effect. Furthermore, phosphorylated penciclovir can be recognized by
cellular enzymes, such as DNA polymerases. As a result, it can be incorporated into DNA
through DNA synthesis process. 4. Penciclovir is favorable for us to use in N4amG
synthesis because it is a commercially available and clinically used medicine with known
pharmacokinetics, pharmacodynamics and toxicity [55].

1.6. Cancer Theranostic Approach
The term “theranostics” was originally used to describe a treatment platform that has
a diagnostic test and a targeted therapy based on the results of the diagnostic test [56].
Currently, “theranostics” has been used in two distinct definitions. The first one defines
“theranostics” as a single technology platform contains both therapeutic and diagnostic
agents. The other is a slightly broader definition. It defines “theranostics” as a personalized
therapeutic treatment based on the results of a separate diagnostic technology [57, 58]. The
following discussion is focused on the narrower definition because from a technology
platform designer’s point of view, it is more valuable to design and develop a single
technology platform, which can diagnose, deliver targeted therapy and monitor the response
to therapy simultaneously.

10

One of the main reasons that cancer treatment still remains challenging is the
heterogeneity and adaptation nature of cancer. To address the challenge, the integration of
diagnostic imaging technologies with therapeutic interventions is crucial. Recently, imaging
technologies have been used increasingly to provide molecular information in anticancer
drug development [59]. Radiotracers with targeting ability make it possible to assess cancer
molecularly through imaging. This information can be used to predict treatment response.
Real-time validation and monitoring of the treatment can be achieved by using imaging
agents during and after chemotherapeutic drugs are delivered. Tumor volume and tumor
cellular death can also be imaged to confirm treatment response[1].

Over the past few decades, with developments in imaging technology, materials
science and cancer biology, a considerable number of theranostic technology platforms have
been developed to diagnose and treat cancer. These technology platforms, such as polymerdrug conjugates and complexes, polymeric micelles, liposomes, dendrimers, polymersomes,
microbubbles, Au/Si/polymer shells and carbon nanotubes, have been well studied and
established [60, 61]. Thus, part of my research was focused on developing a polymeric drug
delivery platform using cancer theranostic concept.

1.7. Polymeric Drug Development and Lead Compound Selection
Among all these technology platforms, according to Siti M. Janib, et.al., “polymerdrug conjugation is a relatively reliable method to improve pharmacokinetics and increase
therapeutic index [62]”. Polymer-drug conjugation is prepared through covalent interactions
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between polymer and drug. The synthetic chemistry pathways used to prepare polymer-drug
conjugates can be various. It often depends on the chemical properties of both carrier and
drug. Current developing polymer-drug conjugates used for theranostics include two major
classes: protein/peptide-based and synthetic polymer-based conjugates.

An example of protein/peptide-based drug conjugation/complexation is albuminbound paclitaxel (trade name Abraxane). It uses a high pressure homogenization method to
form a reversible bond between paclitaxel and albumin [63, 64]. This albumin-bound
paclitaxel significantly reduces the toxicity compared with conventional paclitaxel through
decreased off-target activity [63, 65]. Abraxane treatment was approved by the U.S. Food
and Drug Administration (FDA) in year 2005. Many efforts have been made to conjugate
doxorubicin (DOX) with synthetic polypeptides to increase solubility and reduce off-target
toxicity. For instance, DOX was conjugated to a chimeric polypeptide with a
heterobifunctional linker. The chimeric polypeptide-DOX conjugates are self-assembled to
form nanoparticle like a micelle. This increases the therapeutic index of DOX through
increased plasma circulation and cellular internalization [66-69].

In the category of synthetic polymer-based drug conjugates, N-(2hydroxypropyl)methacrylamide (HPMA) is one of the most wildly studied carriers because
of its low immunogenic and non-toxic properties and circulation stability [70, 71]. A variety
of therapeutic and diagnostic agents have been conjugated with HPMA [72]. For instance, a
131

I labeled HPMA-DOX conjugate for cancer theranostics purposes is currently in clinical

trial [73]. In addition, it has been reported that DOX and gemcitabine were both conjugated
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to HPMA as a single polymer-drugs conjugate [74]. Moreover, using copolymerization
techniques, multimodal diagnostic and therapeutic drugs have been synthesized and
evaluated [75, 76].

The objectives of polymer-drug conjugates are three-fold: 1. increase circulation
time (slow release), 2. decrease toxicity, 3. incorporate targeting moieties to achieve active
tumor targeting functionalities [77-79]. In order to achieve these objectives and, ultimately,
to reach high therapeutic index in cancer theranostic technology platform development, it
would be necessary to design a carrier to target tumor vascular (objective 1 and 2) and
cellular (objective 3) components. Glycopeptide (GP) technology has then been designed
and developed. The structure of GP is a copolymer of chitosan and glutamate peptide.
These two elements give GP the ability to target tumor vasculature endothelial cells and
cellular uptake via glutamate transporters.

Chitosan is known as a biocompatible polymer with wound healing, anti-infection,
anti- inflammatory and tissue adhesive abilities [80-83]. Take wound healing as an example;
chitosan enhances macrophage activation, anti-inflammatory action, angiogenesis
stimulation, granulation and scar formation during the healing process. Many
polysaccharides, including chitosan, chondroitin and hyaluronate have also applied to drug
delivery[84]. Though chitosan has many advantages in medicine, some significant
limitations still remain in the treatment of cancer through intracellular delivery of cytotoxic
drugs. In order to enhance the cell membrane penetrating ability and the therapeutic index
of chitosan in cancer treatment, glutamate peptide was conjugated with chitosan.
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Glutamate is a potent neurotransmitter in the central nervous system and exerts its
action via glutamate transporters [85]. It is also known that cellular uptake of glutamate
peptide is specific to glutamate transporter [86]. Chains of 5 or more glutamic acids could
reduce renal uptake in animal models [87]. In addition, it has been reported that glutamate
peptide-drug conjugates increased drug efficacy [88]. Moreover, glutamate peptidegadolinium complex has been used for MRI applications [89]. Conjugation of GAP with
chitosan resulting GP would be a novel agent to target tumor vascular and cellular
component.

GP has multiple amino and carboxylic acid functional groups, which can be
chemically conjugated with different anti-cancer drugs with carboxylic acid or amino
groups. The carboxylic acids on the glutamate peptide can be used to label different
radioisotopes for different purposes. In other words, GP offers opportunities to combine
passive (tumor vesicular endothelium cell) and active (glutamate transporters) tumor
targeting, molecular imaging (with radiolabeled GP), controlled drug releasing (with GPdrug conjugates) and other theranostic advantages, such as monitor and treat disease
simultaneously.

1.8. Hypothesis and Specific Aims
The background information provided in this chapter clearly supports the concept
that nucleoside transporters and amino acid transporters are upregulated in certain tumor
14

cells. Targeting these transporters can be an effective way to assess tumor cell proliferation
and to deliver anticancer drugs. Collectively, the outlined previously published studies have
let us to hypothesize that radiolabeled N4amG and GP can actively penetrate the cell
membrane through transporters. Furthermore, the retention of radiolabeled N4amG and GP
in tumors will allow specific assessment of tumors. Lastly, I propose that GP-doxorubicin
conjugates will be more specific and less toxic than doxorubicin in tumor treatment. In an
attempt to address this hypothesis, the following Specific Aims were formulated:

Specific Aim 1: To synthesize N4amG and GP, and labeled with 99mTc and 68Ga.

Specific Aim 2: To investigate radiolabeled N4amG and GP in vitro cellular uptake
mechanism and pharmacokinetic accumulation.

Specific Aim 3: To evaluate radiolabeled N4amG and GP imaging potential in tumorbearing animal models.

Specific Aim 4: Proof of concept by conjugating GP with doxorubicin for targeted
chemotherapy in animal models.

This dissertation will highlight the results of studies designed to address these
Specific Aims.
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CHAPTER 2: MATERIALS AND METHODS
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2.1. Reagents, Chemicals and Instrumentation
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl and nuclear and cytoplasmic
extraction reagents (NE-PER) were purchased from Pierce Chemical Company (Rockford,
IL). Chitosan (MW. 3,500-5,000, 75% deacetylated) was obtained from Taiwan Hopax
Chems., Mfg, Company (Kaohsiung, Taiwan). Penciclovir was purchased from LKT
Laboratories (St. Paul, MN). All other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO).

Proton NMR and 13C NMR analyses were performed using a Bruker 300 MHz NMR
spectroscope at the NMR core facility in UT MD Anderson Cancer Center (Houston, TX).
Mass spectral analyses were conducted at the University of Texas M.D. Anderson Cancer
Center (Houston, TX, USA). High resolution Mass spectra (multimode as ion source) were
acquired on an Agilent 6200A accurate Mass time of flight (TOF) system (Santa Clara, CA,
USA). The elemental analysis data were obtained from Galbraith Laboratories (Knoxville,
TN). Radioactive tissue samples were recorded on a Packard gamma counter (Downers
Grove, IL). HPLC analyses were performed using Waters C-18 column (Milford, MA).
Two detectors on HPLC, UV and NaI detectors were used to detect UV absorption and
radioactivity, respectively. Scintigraphic images were obtained from a gamma camera
equipped with low-energy, parallel-hole collimator (M-camera, Siemens Medical Systems,
Inc., Hoffman Estates, IL). MicroPET imaging was obtained from the microPET R4 scanner
(Concord Microsystem, Knoxville, TN). Silica gel coated instant thin-layer chromatography
(ITLC) plates were purchased from Gelman Sciences (Ann Arbor, MI). Silica gel coated
thin-layer chromatography (TLC) plates were purchased from Whatman (Clifton, NJ, USA).
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Spectra/POR molecular porous membrane with cut-off at 5,000 was obtained from Spectrum
Medical Industries Inc. (Houston, TX). Immunofluorescence double staining
deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate-biotin nick end
labeling (TUNEL) assay kit was purchased from Promega Corporation (Madison, WI).
Sodium pertechnetate was obtained from a commercial 99Mo/99mTc generator
(Ultratechnekow FMTM, Mallinckrodt Diagnostics, Houston, TX).

2.2. Animals
All protocols and experiments involving animals (rats, mice and rabbits) were
approved by the M. D. Anderson Animal Care and Use Committee. The animals were
housed in The University of Texas M. D. Anderson Cancer Center facility with controlled
temperature (21-23℃), humidity (50-55%) and light period (on at 0600h, off at 1800h).
Fischer-344 Rats (150±25g) (Harlan Sprague-Dawley, Indianapolis, IN) were inoculated
subcutaneously with rat breast adenocarcinoma cells (13762 NF, 106cells/rodent) into the
right legs. The studies were performed 12 to 15 days after inoculation. Tumor sizes
approximately 0.8-1 cm were measured. During that time, the symmetric site at left legs
was injected with turpentine (0.1 ml) to induce inflammation. New Zealand white rabbits
were purchased from UT MD Anderson Cancer Center ( Houston, TX).
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2.3. Chemistry and Radiochemistry
2.3.1. Synthesis of N2-(p-anisyldiphenylmethyl)-9-[(4-hydroxy)-3-p-anisyldiphenylmethoxymethylbutyl]guanine
Penciclovir (500 mg, 2.43 mmol) was placed in a dry round bottom flask.
Dimethylformamide (DMF, 20 mL) was added followed by methoxytrityl (1.5 g, 4.85
mmol), 4-Dimethylaminopyridine (25 mg), and triethylamine (1.75 mL). The reaction
mixture was under nitrogen gas and was heated at 50℃ for 2 hours with stirring. The
reaction mixture was cooled to room temperature, diluted with methylene chloride, and
washed with water. The aqueous phase was extracted with methylene chloride. The
combined organic phase was dried with anhydrous magnesium sulfate (MgSO4) and
evaporated to yield oily raw product. Silica gel column chromatography was performed
using 5% methanol in dichloromethane. 600 mg of the desired product was obtained in 40%
yield.

2.3.2. Synthesis of N2-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-p-anisyldiphenylmethoxymethylbutyl]guanine
N2-(p-Anisyldiphenylmethyl)-9-[(4-hydroxy)-3-p-anisyl-diphenylmethoxymethylbutyl]guanine (600 mg, 0.76 mmol) was dissolved in anhydrous pyridine (10 mL). PToluene sulfonyl chloride (840 mg, 4.3 mmol) was added. The reaction mixture was stirred
at room temperature for 3 h. The reaction mixture was diluted with methylene chloride, and
washed with water. The aqueous phase was extracted with methylene chloride. The
combined organic phase was dried with anhydrous MgSO4 and evaporated to yield the crude
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product. Silica gel column chromatography was performed using 5% methanol in
dichloromethane. 250 mg of the desired product was obtained in 34% yield.

2.3.3. Synthesis of 9-[4-amino-3-(hydroxymethyl)butyl]guanine (NH2-Guan, compound I)
N2-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-panisyldiphenylmethoxymethylbutyl]guanine (250 mg, 0.38 mmol)was placed in a
dry round bottom flask. 10 mL DMF and sodium azide (80 mg, 1.2 mmol) was
added. The reaction mixture was stirred at 100oC for 2 hours. The reaction mixture
was cooled to room temperature, and diluted with dichloromethane followed by
water washing. The aqueous phase was extracted with dichloromethane. The
combined organic phase was dried with anhydrous MgSO4 and evaporated to yield
the crude product. 225 mg of the crude azido compound was obtained. 1H NMR
(CDCl3): δ 8.04 (s, 1H), 7.22-7.45 (m, 20H), 6.86 (d, 4H, J = 9.0 Hz), 6.78 (d, 4H, J
= 9.0 Hz), 3.79 (s, 3H), 3.76 (s, 3H), 3.55-3.65 (m, 2H), 3.25-3.35 (m, 2H), 1.63-1.73
(m, 2H), 1.32-1.42 (m, 1H), 1.16 (d, 2H, J = 3.6 Hz). Exact mass calculated for
C50H46N8O4 [M + H] + 823.3641 found 823.4025.
The crude azido compound (225 mg) was dissolved in anhydrous
tetrahydrofuran (30 mL) and triphenylphosphine (325 mg, 1.3 mmol) was added.
The reaction mixture was stirred at room temperature for 16 hours. Hydrochloric
acid (HCl 5N, 1 mL) was added to the reaction mixture and the whole flask was
heated under reflux for 5 hours. The reaction mixture was cooled to room
temperature and was filtered. The solution was evaporated to dryness. The residue
was dissolved with water and washed with ethylene chloride. Sodium hydroxide (1N,
3.5 mL) was added in drop-wise manner to adjust the pH to 7-8. Sephadex-G15
column chromatography was performed to separate the desired product from
impurities. After freeze drying (Labconco, Kansas City, MO), 50mg of the desired
product (compound 1) was obtained in 76% yield. Ninhydrin (2% in methanol) spray
test demonstrated the presence of amino group. Proton and 13C NMR were
performed. 1H NMR (CDCl3): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m,
2H), 2.90 (d, 2H, J = 6.0 Hz), 1.72 (m, 2H), 1.43 (m, 1H). FAB MS: 253 [M + H] +
[55].

2.3.4. Synthesis of Cyclam-(BOC)3
1,4,8,11-tetraazacyclotetradecane (cyclam) (2 g, 9.98 mmol) was dissolved in
methylene chloride. Di-tert-butyl dicarbonate (BOC) (5 g, 22.91 mmol) was added to
the cyclam solution. The resulting solution was stirred at room temperature for 2
hours. Then, the reaction was stopped and solvent was evaporated by a rotary
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evaporator. After solvent evaporation, silica gel column chromatography was
performed using methanol/ methylene chloride system. 4.81 g of the desired product,
Cyclam-(BOC)3 was obtained in 86% yield. Proton NMR and mass spectrometry
analyses were conducted. 1H NMR (CDCl3): δ 3.08-3.22 (m, 12H), 2.81 (m, 2H),
2.55 (m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for
C25H49N4O6 (M + H) + 501.3574 found 501.3648 [55].

2.3.5. Synthesis of Cyclam-(BOC)3-EA
Cyclam-(BOC)3 (6.53 g, 13 mmol) was dissolved in 20 mL of DMF. Ethyl
bromo acetate (1.34 mL) and potassium carbonate (2.70 g, 19.5 mmol) was added to
the solution, and the reaction mixture was stirred under nitrogen gas and condenser
at 80-85℃ for 16 hours. The reaction mixture was filtered. After filtration, the
filtrate was placed in a rotary evaporator for solvent evaporation. After solvent
evaporation, extraction was performed twice with chloroform as the organic layer
and water as aqueous layer. The organic layer was dried with magnesium sulfate and
filtered. After solvent evaporation, silica gel column chromatography was performed
using a methanol/ methylene chloride system. 7.21 g of the desired product, Cyclam(Boc)3-EA was obtained in 83% yield. Proton NMR and mass spectrometry analyses
were conducted. 1H NMR (CDCl3): δ 4.31 (m, 2H), 3.32 (s, 2H), 3.08-3.22 (m, 12H),
2.81 (m, 2H), 2.55 (m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H), 1.29 (m, 3H).
Exact mass calculated for C29H55N4O8 [M + H]+ 587.3942 found 587.5961 [55].

2.3.6. Synthesis of Cyclam-(BOC)3-AA
Cyclam-(BOC)3-EA (4.58 g, 7.8 mmol) was dissolved in 30 mL methanol.
NaOH (1 N, 15.5ml) was added for hydrolysis. The reaction mixture was stirred at
room temperature for 2 hours. Methanol solvent was evaporated by a rotary
evaporator and the remaining aqueous layer was acidified with 1M HCl until pH
dropped to 6. Extraction was performed twice with ethyl acetate. Ethyl acetate layer
was dried with magnesium sulfate, filtered and after solvent evaporation, cyclam(BOC)3-AA was collected. Proton NMR and mass spectrometry analyses were
conducted. 1H NMR (CDCl3): δ 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.81 (m, 2H), 2.55
(m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for
C27H51N4O8 [M + H] + 559.3629 found 559.5141 [55].
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2.3.7. Synthesis of Cyclam Mono acid-9-[4-amino-3-(hydroxymethyl)butyl]guanine
Conjugate (N4amG)
Cyclam-(BOC)3-AA (50 mg, 0.19 mmol) was dissolved in water (5 ml). To
this colorless solution, sulfo-N-hydroxysuccinimide (sulfo-NHS, 95.5 mg, 0.44
mmol), 3-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl (EDC, 84.5 mg, 0.44
mmol) and compound I (50 mg, 0.20 mmol) were added. The mixture was stirred at
room temperature for 16 hours. The mixture was frozen dried. 10 mL 50%
trifluoroacetic acid in methylene chloride was added to the dried residues. The
reaction mixture was stirred at 50℃ for 30 minutes. Solvent was evaporated by a
rotary evaporator and the remaining compounds were dissolved in water. The
aqueous layer was dialyzed for 24 hours using a Spectra/POR dialysis membrane
with molecular weight cut-off at 500 Da. (Spectrum Medical Industries Inc., Houston
TX). After freeze drying, 50mg of the desired product (N4amG) was obtained in
58% yield. Mass spectronmetry and HPLC analysis were performed. The purity is
>97%. 1H NMR (D2O): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m, 2H),
3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.90 (d, 2H, J = 6.0 Hz), 2.81 (m, 2H), 2.55 (m,
2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.67 (m, 2H), 1.43 (m, 1H). Exact mass calculated
for C22H41N10O3 [M + H] + 493.3285 found 493.3340 [55].

2.3.8. Radiolabeling of N4amG with99mTc
N4amG (5 mg) was dissolved in 0.2 ml distilled water. Subsequently, 0.1 mL
Tin(II) chloride solution (1 mg in 1 ml of water) and sodium pertechnetate
(Na99mTcO4, 1.0 mCi, Mallinckrodt, Houston, TX) were added sequentially. The
total volume was adjusted to 1.0 mL by adding adequate amount of distilled water.
The reaction mixture was kept at room temperature for 10 minutes. The specific
activity was 5 mg/1 mCi/ml. Radiochemical purity was determined by TLC (ITLC
SG, Gelman Sciences, Ann Arbor, MI) eluted with saline. From radio-TLC analysis
(Bioscan, Washington, DC) and HPLC analysis (Waters, Milford, MA), the
radiochemical purity was more than 95% [55].

2.3.9. Radiolabeling of N4amG with 68Ga
Radiolabeling of N4amG with 68Ga was performed in a standard manner [53].
Briefly, N4amG (5 mg) was dissolved in 0.2 ml of water, and 68Ga chloride (5 mCi)
evaporated to dryness and reconstituted in 0.1 ml of sterilized water at room temperature,
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followed by heating up to 55°C for 10 minutes. Radiochemical purity was determined by
radio-HPLC.

2.3.10. Synthesis of Glycopeptide (GP)
To a stirred solution of chitosan (200 mg, MW. 3,500-5,000) in water (4 ml)
EDC (128.5 mg, 0.67 mmol) was added. Glutamate peptide sodium salt (200 mg,
MW. 1,308) was then added. The mixture was stirred at room temperature for 24
hours. The mixture was dialyzed for 48 hours using a Spectra/POR molecular
porous membrane with cut-off at 5,000 (Spectrum Medical Industries Inc., Houston,
TX). After dialysis, the product was filtered and dried using a freeze dryer
(Labconco, Kansas City, MO). The GP in the salt form weighed 320 mg [90].

2.3.11. Synthesis of Re-GAP
Rhenium chemistry has been used to support the binding site or structure of
Tc [91]. It is known that 99mTc binds to GP through the carboxylic acid moiety of
glutamate peptide. Thus, glutamate peptide was selected for Re-chemistry instead of
GP. Rhenium oxotrichloride (ReOCl3) and triphenylphosphine (41.7 mg, 0.05
mmol) were added to glutamate peptide (65.5 mg, 0.05 mmol) in a mixture of
ethanol (3 mL) and DMF (5 mL) solution. The reaction was refluxed for 30 minutes.
The solution was filtered and the solvent was evaporated to dryness, yielded 30 mg
(40%). Proton and 13C NMR spectra were performed to determine the structure of
Re-glutamate peptide [92].
99m

2.3.12. Synthesis of GP-Doxorubicin (GP-DOX)
Glutamate peptide sodium salt (500.0 mg) was dissolved in water (6 mL), and the
solution was cooled to 0°C. Diluted HCl solution (1.0 M) was added drop wise with stirring
until the pH was between pH 2 to 2.5. During the addition, the glutamate peptide separated
out of solution. The reaction mixture was warmed to room temperature and stirred for 1
hour. The solid was filtered and washed with water. The solid was lyophilized. Yield 300.0
mg.
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10 mL of anhydrous DMF was added to 200 mg of glutamate peptide and stirred to
get it dissolved. 35.6 mg of NHS was added followed by the addition of 63.9 mg of 1,3dicyclohexylcarbodiimide (DCC). The mixture was stirred for 30 minutes. 180 mg of
doxorubicin HCl was dissolved in 4mL of DMF and 51.84 µL of triethylamine and it was
then added to the mixture of GAP, DCC and NHS solution. The final reaction mixture was
stirred overnight. Next day the solution was filtered and the filtrate was evaporated under
high vacuum. The residue was dissolved with sodium bicarbonate solution (1 N). The
solution was filtered with a 45 µm filter and it was then dialyzed with a membrane of
MWCO 1000 for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after
lyophilization 230.0 mg.

GAP-DOX 200mg was dissolved in 5 mL water. 19.16mg of EDC was added and
stirred for 10 minutes then 30 mg of chitosan was added. The mixture was stirred overnight.
Next day the solution was filtered and the filtrate was dialyzed with 1000MWCO membrane
for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after lyophilization
210 mg. Conjugation of doxorubicin was 33.5% (w/w) measured by UV spectroscopy
method at wavelength 480nm.

2.3.13. Synthesis of GP-Pamidronate (GP-PAM)
300 mg of poly glutamic acid sodium salt was dissolved in 5 mL of water. 107.6 mg
of EDC was added and the mixture was stirred for 10 minutes. Meanwhile 110 mg of
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pamidronic acid was dissolved in water with 1 (N) sodium hydroxide and it was then added
to the GAP-EDC solution and stirred for overnight. Next day the solution was filtered and
the filtrate was dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution
was frozen and lyophilized.

150 mg of GAP-pamidronic acid was dissolved with water (5mL). 9.8mg of EDC
was added and stirred for 10 minutes. Thereafter, 15 mg of chitosan was added and the
mixture was stirred for overnight. Next day the solution was filtered and the filtrate was
dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution was frozen and
lyophilized.

2.3.14. Synthesis of GP-Methotrexate (GP-MTX)
250 mg of methotrexate was dissolved with 1 (N) sodium hydroxide. 126 mg of EDC
was added and stirred for 15 minutes. Meanwhile 1.0 gram of chitosan was dissolved in 8
mL of water. The MTX solution was added to the chitosan solution. The mixture was stirred
overnight. Next day the solution was filtered and the filtrate was dialyzed with 1000MWCO
membrane for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after
lyophilization 690 mg.

97.5 mg of glutamate peptide sodium salt was dissolved in water (4mL). EDC was
added (156 mg) and stirred for 10 minutes. Meanwhile chitosan-Methotrexate (650 mg) was
dissolved in 8 mL of water and it was added to the upper solution and the mixture was
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stirred for overnight. Next day the solution was filtered and the filtrate was dialyzed with
1000MWCO membrane for 24 hours. The dialyzed solution was frozen and lyophilized.
Yield after lyophilization 710 mg. Methotrexate conjugation rate was 29.9% (w/w)
calculated by UV spectroscopy at a wavelength of 370 nm.

2.3.15. Synthesis of GP-folate (GP-FOL)
242.8 mg of folic acid was dissolved with 1 (N) sodium hydroxide. 122 mg of EDC
was added and stirred for 15 minutes. Meanwhile 1.0 gram of chitosan (Mw 5849) was
dissolved in 8 mL of water. The folate solution was added to the chitosan solution. The
mixture was stirred overnight. Next day the solution was filtered and the filtrate was
dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution was frozen and
lyophilized. Yield after lyophilization 678 mg.

97.5 mg of glutamate peptide sodium salt was dissolved in water (4mL). EDC was
added (156 mg) and stirred for 10 minutes. Meanwhile chitosan-Folate (650 mg) was
dissolved in 8 mL of water and it was added to the upper solution and the mixture was
stirred for overnight. Next day the solution was filtered and the filtrate was dialyzed with
1000MWCO membrane for 24 hours. The dialyzed solution was frozen and lyophilized.
Yield after lyophilization 710 mg. folic acid conjugated was 28.7% (w/w) calculated by UV
spectroscopy at a wavelength of 370 nm.
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2.3.16. Radiolabeling of GP with 99mTc
Radiolabeling of GP with 99mTc was performed in a standard manner [93].
Briefly, GP (5 mg) was dissolved in 0.2 ml of water and tin chloride (0.1 mg in 0.1
ml of water) was added at room temperature. Sodium pertechnetate (5 mCi) was
added. Radiochemical purity was determined by instant thin-layer chromatography
(ITLC SG, Gelman Sciences, Ann Arbor, MI) eluted with saline [92].

2.3.17. In vitro Stability Assays of 99mTc-GP
To demonstrate serum stability of 99mTc-GP, 99mTc-GP was prepared in the
concentration of 10 mg/1 mCi/ml. GP was prepared in the concentration of 10mg/ml
and Na99mTcO4 (1 mCi) were added. 0.1 mL of 99mTc-GP was incubated with 0.1
mL phosphate buffered saline (PBS, pH=7.4) at 0.5-24 hours. In vitro stability of
99m
Tc-GP was determined by chromatographic analysis as described in the above
section [92].

2.3.18. Radiolabeling of GP with 68Ga
Radiolabeling of GP with 68Ga was performed in a standard manner [94].
Briefly, GP (5 mg) was dissolved in 0.2 ml of water, and 68Ga chloride (5 mCi)
evaporated to dryness and reconstituted in 0.1 ml of sterilized water at room
temperature, followed by heating up to 55oC for 10 min. Radiochemical purity was
determined by ITLC eluted with saline [90].

2.3.19. In vitro Stability Assays of 68Ga-GP
68

Ga-GP was prepared in the concentration of 5 mg/1 mCi/ml. 0.1mL of
Ga-GP was incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 37℃ for
30-120 minutes. In vitro stability of 68Ga-GP was determined by chromatographic
analysis, as described in section 2.3.17 [90].
68

2.3.20. Radiolabeling of GP-drug Conjugates with 99mTc
Radiolabeling of GP-drug conjugates with 99mTc was performed in a standard
manner[93]. Briefly, GP-drug conjugates (5 mg) were dissolved in 0.2 ml of water and tin
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chloride (0.1 mg in 0.1 ml of water) was added at room temperature. Sodium pertechnetate
(5 mCi) was added. Radiochemical purity was determined by elution with saline.
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2.4. Pharmacology and Toxicology
2.4.1. In Vitro Cell Culture Assay of 99mTc-N4amG
To evaluate whether 99mTc-N4amG can penetrate the cell membrane, an in
vitro cellular uptake study using 99mTc-N4amG and its chelator control (99mTc-N4)
was conducted. Cells in a 12-well plate (50,000 cells/ well) were incubated with
99m
Tc-N4amG or 99mTc-N4 at 37℃ for 30 minutes, 2 hours or 4 hours. Following the
incubation period, cells were washed with PBS twice and detached with 0.5 mL of
trypsin solution. After centrifugation, radioactivity was measured by a gamma
counter. Data was processed and presented in mean ± S.D. [55].

2.4.2. Cellular Fraction Assay of 99mTc-N4amG
To determine the distribution pattern of 99mTc-N4amG within the cells, NE–
PER extraction reagents were used stepwise to isolate cytoplasmic and nuclear
extracts from breast cancer cells. 99mTc-N4amG (0.1 mCi) was prepared in the
concentration of 0.1 mg/mL. After 20 ml of 99mTc-N4amG (0.02 mg/well, 2 mCi) or
99m
Tc-N4 (control) was dispensed into each well of a 6-well plate, and cells (50,000
per well) were incubated at 37℃ for 2 hours. Cells were transferred to a 2 mL
microcentrifuge tube and isolated by centrifugation at 500 g for 2–3 minutes. 200 μL
of ice-cold kit reagent (CER I) was added to the cell pellet in other remaining tubes.
Following 10 minutes of incubation, 11 μL of ice cold CER II was added and
incubated for an additional 1 minute. The tubes were centrifuged for 5 minutes at
maximum speed in a microcentrifuge and the supernatant (cytoplasmic extract)
fractions were transferred to other tubes for counting. Insoluble (pellet) fractions,
which contain nuclei, were resuspended in 100 μL of ice-cold NER. Following a
total 40 minutes of incubation, the tubes were re-centrifuged at a maximum speed for
10 minutes and the supernatant (nuclear extract) fractions were transferred to other
tubes for counting. Insoluble (pellet) fraction, which contains nuclear material, was
resuspended in 100 μL of PBS and transferred to other tubes for counting. Samples
were counted in a gamma counter [55].

2.4.3. Cellular Blocking Assay of 99mTc-N4amG
To determine whether cellular uptake of 99mTc-N4amG was via a nuclear transporter,
the breast tumor cells were incubated with guanine (specific) or glucose at 0.25-1.0 mg/well
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for 30 minutes, followed by 99mTc-N4amG (4 µCi/well, 0.02 mg/well). The cells were
incubated for an additional 20 minutes.

2.4.4. Cell Sorting Assay of 99mTc-N4amG
To further investigate whether different cell cycle phases have different capacity in
the uptake of 99mTc-N4amG, cell sorting assay was conducted. 1-2×106 cells were harvested
and then suspended in 1 mL media. The Hoeches 33342 reagent (prepared in 1 mM stock
solution) was added to cell suspension to a final concentration of 10 μM. Cells were
incubated at 37℃ for 1 hour. After incubation, cells were analyzed and sorted by flow
cytometry.

Cells were sorted into the various phases of cell cycle (G0/G1, S, and G2/M)
using fluorescence activated cell sorter (FACS). Sorted cells were suspended in
15mL test tubes (50,000 cells/ tube). 99mTc-N4amG or 99mTc-N4 was added, and the
cells were incubated at 37℃ for 60 minutes. Following the incubation period, cells
were centrifuged and washed with PBS twice. After final centrifugation,
radioactivity was measured by gamma counter. Data was processed and presented in
mean ± S.D. [55].

2.4.5. Biodistribution Studies of 99mTc-N4amG and 99mTc-MIBI in Rats
Female Fischer 344 rats (150–175 g) were inoculated subcutaneously in the
right leg with 13762 rat breast cancer cells (106 cells/rat) from the breast cell line.
Biodistribution studies were performed on day 14 after inoculation. 9 tumor-bearing
rats were used and divided into three groups, each group representing a time interval
(0.5, 2, and 4 hr, n=3/time point). 20 Ci of 99mTc-N4amG was injected via a lateral
tail vein. After administration of the radiotracers, the rats were sacrificed at 0.5, 2
and 4 hours and the selected tissues were excised, weighed and counted for
radioactivity with a gamma counter. The distribution of radiotracer in each organ
was expressed as percentage of the injected dose per gram of tissue (%ID/g).
Tumor-to-muscle and tumor-to-blood count ratios were determined from the
30

corresponding %ID/g values. In statistical analysis, percent of injected dose per gram
of tissue weight (%ID/g) and tumor-to-tissue ratios used in biodistribution studies
were presented as mean ± S.D. [55].
99m

Tc-methoxyisobutylisonitrile (99mTc-MIBI) was prepared by adding 9.6 mCi of

99m

Tc-sodium pertechnetate to MIBI kit (INER, Taiwan). Normal saline was added until the

total volume reached to 9.6 mL (strength: 9.6 mCi/9.6 mL/kit). The vial was incubated in
boiling water for 15 minutes then cooled-down in room temperature for 15 minutes.

Female Fischer 344 rats (150–175 g) were inoculated subcutaneously in the right leg
with 13762 rat breast cancer cells (106 cells/rat) from the breast cell line. Biodistribution
studies were performed on day 14 after inoculation. 12 tumor-bearing rats were used and
divided into three groups, each group representing a time interval (15 min, 45 min, 2 and 4
hr, n=3/time point). 20 Ci of 99mTc-MIBI was injected via a lateral tail vein. After
administration of the radiotracers, the rats were sacrificed at 15, 45 minutes, 2, and 4 hours
and the selected tissues were excised, weighed and counted for radioactivity with a gamma
counter. The distribution of radiotracer in each organ was expressed as percentage of the
injected dose per gram of tissue (%ID/g). Tumor-to-muscle and tumor-to-blood count ratios
were determined from the corresponding %ID/g values. In statistical analysis, percent of
injected dose per gram of tissue weight (%ID/g) and tumor-to-tissue ratios used in
biodistribution studies were presented as mean ± S.E.M.
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2.4.6. Olinda Dosimetry Estimation of 99mTc-N4amG in Rats
Human radiation dose estimates for 99mTc-N4amG were computed through
Olinda/EXM software (Oakridge, TN) [95] from their respective biodistribution data.
Olinda inputs were calculated using established methods [90, 92]. Briefly, fitted
residence time functions were plotted and multiplied by the exponential decay
functions (i.e., half-life) for 99mTc. These functions were then integrated analytically
to determine the area under the curve (AUC) to yield the residence time of each
organ. Mass correction factors were used to account for the different ratios of organ
to total body weights in the rat and in humans, and allowed for the scaling of the rat
residence times to human residence times. Residence times were then used to
calculate target organ absorbed radiation doses with S-value tables for a standard 70
kg male model using the Olinda software package. Each organ dose was computed
from the sum of self-dose plus the dose it received from each source organ in the
body or from the remainder of the body. The estimated human radiation absorption
dose was determined [55].

2.4.7. Scintigraphic Imaging Studies of 99mTc-N4amG in Rats
To demonstrate the application of 99mTc-N4amG in breast tumor imaging,
three breast tumor-bearing rats were administered with 99mTc-N4amG (300 µCi/rat,
1.0 mg physical amount, iv.) Scintigraphic images, using a gamma camera equipped
with low-energy, parallel-hole collimator, were obtained after 1, 2 and 4 hours. The
standard source used for calibration was 30 µCi of Na99mTcO4. Computer outlined
region of interest measures (counts per pixel) of the tumor and muscle (at the
symmetric site) were used to determine tumor-to-muscle count density ratios [55].

2.4.8. Scintigraphic Imaging Studies of 99mTc-N4amG in Rats, Pre- and Post- Treatment
To demonstrate the application of 99mTc-N4amG in monitoring treatment response,
three 13762 rat breast tumor-bearing rats were administered with 99mTc-N4amG (300 μCi/rat,
3 mg physical amount, iv) at pre- and post-paclitaxel treatment (20 mg/kg, iv, single dose) at
72 hours. Scintigraphic images, using a gamma camera equipped with low-energy, parallelhole collimator, were obtained 0.5 and 1 hour. The standard source used for calibration was
30 μCi of Na99mTcO4. Computer outlined region of interest measures (counts per pixel) of
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the tumor and muscle (at the symmetric site) were used to determine tumor-to-muscle count
density ratios.

2.4.9. Scintigraphic Imaging Studies of 99mTc-N4amG in Tumor/Inflammation Animal
Model
To demonstrate differential diagnosis of 99mTc-N4amG between tumor and
inflammation, the left legs of 13762 breast tumor-bearing rats (tumor model described in
section 2.4.5.) were administered with turpentine (0.1 mL, i.m.). The following day, breast
tumor-bearing rats were administered with 99mTc-N4amG(300 µCi/rat, 3 mg physical
amount, iv.) and scintigraphic images, were obtained 2 hours. The standard source used for
calibration was 30 μCi of Na99mTcO4. Computer outlined region of interest measures
(counts per pixel) of the tumor and muscle; tumor and inflammation (at the symmetric site)
were used to determine count density ratios.

2.4.10. Ki-67 Staining Assay
To further investigate the correlation between 99mTc-N4amG tumor uptake and cell
proliferation marker, Ki-67, tumors were excised from non-treated and paclitaxel-treated
(20mg/kg, iv. single dose, after 72 hours) rats. The tumor blocks were preserved in 10%
formalin (approx. 4% formaldehyde) before being sent to the histopathology core facility for
H&E staining and Ki-67 staining.
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2.4.11. Kinetic Study of Blood Clearance of 99mTc-N4amG in Rats
Fischer-344 rats were administered intravenously 2 mCi of 99mTc-N4amG. To
determine blood clearance and biological half-life of 99mTc-N4amG, 0.1ml blood samples
were collected from 10 seconds to 20 minutes (14 time points) after injection. Blood
samples were weighed and the radioactivities were counted by gamma counter. The
radioactivity of each sample was calculated as a percentage of the injected dose per gram of
the blood’s net weight (%ID/g).

2.4.12. In Vitro Cell Culture Assay of 68Ga-N4amG
Cells in a 12-well plate (50,000 cells/ well) were incubated with 68Ga-N4amG or
68

Ga-N4 at 37℃ for 30 minutes, 1 hour, 2 hours or 4 hours. Following the incubation period,

cells were washed with PBS twice and detached with 0.5 mL of trypsin solution. After
centrifugation, radioactivity was measured by a gamma counter. Data were processed and
presented in mean ± S.D.

2.4.13. In Vitro Cell Culture Assays of 99mTc-GP
13762 cells were plated to a 12-well tissue culture plate that contained 50,000
cells per each well. The cells were incubated with 99mTc-GP (2 μCi/well, 0.02
mg/well) at 37℃ for 0.5-6 hours. After incubation, cells were washed with ice-cold
phosphate-buffered saline PBS twice and trypsinized with 0.5 mL of trypsin solution
to detach tumor cells. Then cells were collected by centrifugation. The cells were
weighed and the radioactivity was measured by a gamma counter. Data were
expressed in mean ± S.D. percent of cellular uptake per mg of cell weight from three
measurements [92].
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2.4.14. Cellular Fraction Assay of 99mTc-GP
To determine the distribution pattern of 99mTc-GP within the cells, NE-PER
extraction reagents were used stepwise to isolate cytoplasmic and nuclear extracts
from 13762 rat breast cancer cells. 99mTc-GP (0.1 mCi) was prepared in the
concentration of 0.1 mg/mL. After 20 µl of 99mTc-GP (0.02 mg/well, 2 µCi) or
Na99mTcO4 (control) was dispensed into each well of a 6-well plate, cells
(50,000/well) were incubated at 37℃ for 2 hours. Cells were transferred to a 2 mL
microcentrifuge tube and isolated by centrifugation at 500 g for 2-3 minutes. 200 µL
of ice-cold kit reagent (CER I) was added to the cell pellet in other remaining tubes.
Following 10 minutes of incubation, 11 µl of ice-cold CER II was added and
incubated 1 more minute. The tubes were centrifuged for 5 minutes at maximum
speed in a microcentrifuge (~16,000 x g) and the supernatant (cytoplasmic extract)
fractions were transferred to other tubes for counting. Insoluble (pellet) fractions,
which contain nuclei, were resuspended in 100 µL of ice-cold NER. Following a
total of 40 minutes incubation, the tubes were re-centrifuged at a maximum speed
(~16,000 x g) for 10 minutes and the supernatant (nuclear extract) fractions were
transferred to other tubes for counting. The insoluble (pellet) fraction, which contains
nuclear material, was resuspended in 100 µL of 1 x PBS and transferred to other
tubes for counting. Samples were counted in a gamma counter [92].

2.4.15. Cellular Uptake Assay of 99mTc-GP, Pre- and Post- Treatment
To determine whether 99mTc-GP could monitor post-treatment changes,
13762 rat breast tumor cells (50,000 per each well) were incubated with paclitaxel
(1-5 µM) for 48 hours. 99mTc-GP was prepared in the concentration of 0.1 mg/0.1
mCi/mL. 99mTc-GP (2 μCi/well, 0.02 mg/well) was added to the wells and incubated
for 4 hours before and after paclitaxel treatment. TUNEL assays were used to
assess paclitaxel-induced apoptosis in these cells. TUNEL assays were described in
our previously published procedure [96]. To determine whether cellular uptake of
99m
Tc-GP was via a glutamate transporter, the breast tumor cells were incubated with
glutamate (specific) or aspartate (non-specific) at 0.05-0.3 mg/well, followed by
99m
Tc-GP (2 μCi/well, 0.02 mg/well). The cells were incubated for an additional 30
minutes. After incubation, cells were washed and trypsinized as described
previously [92].

2.4.16. Cellular Blocking Assay of 99mTc-GP
To determine whether cellular uptake of 99mTc-GP was via a glutamate
transporter, the breast tumor cells were incubated with glutamate (specific) or
aspartate at 0.05-0.3 mg/well for 30 minutes, followed by 99mTc-GP (4 µCi/well,
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0.02 mg/well). The cells were incubated for additional 20 minutes. After incubation,
cells were washed and trypsinized as described previously [92].

2.4.17. Biodistribution Studies of 99mTc-GP in Rats
Female Fischer 344 rats (150-175 g) were inoculated subcutaneously in the
right leg with 13762 rat breast cancer cells (106 cells/rat) from the breast cell line.
Biodistribution studies were performed on day 14 after inoculation. A group of
Female Fischer 344 tumor-bearing rats was injected intravenously with 99mTc-GP (30
μCi/rat, n=3 rats/time point) through the tail vein. The injected mass was 30 μg per rat.
At 30 minutes, 3, 5 and 24 hours following administration of the radiotracers, the
animals were sacrificed and the tumors and selected tissues were excised, weighed, and
counted for radioactivity with a gamma counter. The biodistribution of 99mTc-GP in
each sample was calculated as a percentage of the injected dose per gram of the tissue’s
wet weight (%ID/g) [92].

2.4.18. MIRD Dosimetry Estimates of 99mTc-GP in Rats
Rat absorbed doses estimates for 99mTc-GP were computed from their
respective biodistribution data. Fitted residence time functions were plotted and
multiplied by the exponential decay functions (i.e., half-life) for 99mTc. These
functions were then integrated analytically to determine the area under the curve
(AUC) to yield the residence time of each organ. It was assumed that the injected
activity distribution was uniformly distributed throughout the body immediately
following injection. It was further assumed that no excretion occurred after the last
time point and that the activity distribution remained unchanged after this time point,
i.e., no biological excretion was assumed past the last time point. Mass correction
factors were used to account for the different ratios of organ to total body weights in
the rat and in humans, and allowed for the scaling of the rat residence times to
human residence times. For the organs where total organ weight was unavailable, the
organ weights derived from the Cristy-Eckerman mathematic phantoms [97] for the
adult male were used to estimate total tissue activity. Residence times were then
used to calculate target organ absorbed radiation doses with S-value tables for a
standard 70 kg male model using the MIRDose 3.1 software package. Each organ
dose was computed from the sum of the self-dose plus the dose it received from each
source organ in the body or from the remainder of the body[92, 98].
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2.4.19. Scintigraphic Imaging Studies of 99mTc-GP in Rats
To demonstrate the application of 99mTc-GP in monitoring treatment
response, three 13762 breast tumor-bearing rats were administered with 99mTc-GP
(300 μCi/rat, 3 mg physical amount, iv) at pre- and post-paclitaxel treatment (60
mg/kg, iv., single dose) at 48 hours. Scintigraphic images, using a gamma camera
equipped with low-energy, parallel-hole collimator, were obtained 0.5 and 1 hour.
The standard source used for calibration was 30 μCi of Na99mTcO4. Computer
outlined region of interest measures (counts per pixel) of the tumor and muscle (at
the symmetric site) were used to determine tumor-to-muscle count density ratios [92].

2.4.20. Scintigraphic Imaging Studies of 99mTc-GP in Rats with and without Inflammation
To demonstrate differential diagnosis of 99mTc-GP between tumor and
inflammation, the left legs of breast tumor-bearing rats (tumor model described in
previous Biodistribution Studies) were administered with turpentine (0.1 mL, i.m.).
The following day, breast tumor-bearing rats were administered with 99mTc-chitosan,
99m
Tc-glutamate peptide and 99mTc-GP (300 µCi/rat, 3 mg physical amount, iv.) and
scintigraphic images, were obtained 2 hours. The standard source used for calibration
was 30 μCi of Na99mTcO4. Computer outlined region of interest measures (counts
per pixel) of the tumor and muscle; tumor and inflammation (at the symmetric site)
were used to determine count density ratios [92].
2.4.21. Kinetic study of blood clearance of 99mTc-GP in New Zealand white rabbit
New Zealand white rabbits were administered intravenously 2 mCi of 99mTc-GP. To
determine blood clearance and biological half-life of 99mTc-GP, 0.1 ml blood samples were
collected from 10 seconds to 20 minutes (14 time points) after injection. Blood samples were
weighed and the radioactivities were counted by gamma counter. The radioactivity of each
sample was calculated as a percentage of the injected dose per gram of the blood’s net weight
(%ID/g).
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2.4.22. Biodistribution Studies of 68Ga-GP in Rats
Female Fischer 344 rats (150-175 g) were inoculated subcutaneously in the
right leg with breast cancer cells (106 cells in 0.1mL/rat) from the 13762 cell line.
Biodistribution studies were performed on day 14 after inoculation. A group of
Female Fischer 344 tumor-bearing rats was injected intravenously with 68Ga-GP or 18FFDG (30 μCi/rat, n=3 rats/time point) through the tail vein. The injected mass was 30
μg of 68Ga-GP per rat. At 30, 60, 120 min following administration of the radiotracers,
the animals were sacrificed and the tumors and selected tissues were excised, weighed,
and counted for radioactivity with a gamma. The biodistribution of 68Ga-GP or 18FFDG in each sample was calculated as a percentage of the injected dose per gram of the
tissue’s wet weight (%ID/g) [90].

2.4.23. MIRD Dosimetry Estimates of 68Ga-GP in Rats
Rat absorbed doses estimates for 68Ga-GP were computed from their
respective biodistribution data. Fitted residence time functions were plotted and
multiplied by the exponential decay functions (i.e., half-life) for 68Ga-GP. These
functions were then integrated analytically to determine the area under the curve
(AUC) to yield the residence time of each organ. It was assumed that the injected
activity distribution was uniformly distributed throughout the body immediately
following injection. It was further assumed that no excretion occurred after the last
time point and that the activity distribution remained unchanged after this time point,
i.e., no biological excretion was assumed past the last time point. Mass correction
factors were used to account for the different ratios of organ to total body weights in
the rat and in humans, and allowed for the scaling of the rat residence times to
human residence times. For the organs where total organ weight was unavailable,
the organ weights derived from the Cristy-Eckerman mathematic phantoms for the
adult male were used to estimate total tissue activity. Residence times were then used
to calculate target organ absorbed radiation doses with S-value tables for a standard
70 kg male model using the MIRDose Olinda software package (Oakridge, TN).
Each organ dose was computed from the sum of the self-dose plus the dose it
received from each source organ in the body or from the remainder of the body. The
estimated human radiation absorption dose was determined [90].

2.4.24. PET Imaging Studies of 68Ga-GP in Rats and Rabbits
For microPET imaging, the images were acquired on a microPET R4
scanner, a dedicated 3D small-animal PET (Concorde Microsystems, Knoxville TN).
A group of 13762 tumor-bearing female Fischer 344 rats was injected intravenously
with 68Ga-GP or 18F-FDG (n=3 rats/compound) through the tail veins. Each animal
was anesthetized and secured in the microPET. Cradle notches, laser lights and
38

animal felt pen markings were used to insure reproducible animal positioning before
and after administration of 68Ga-GP and 18F-FDG. Each animal was injected with
1.62 μCi/g body weight of 68Ga-GP and 18F-FDG and imaged for 2 hr in a dynamic
mode. A minimum of ~20 million events were acquired in 120 minutes covering the
tumor bearing area. The acquired list mode data was then histogramed into frames of
varying durations using Fourier rebinning. The corresponding images were
reconstructed into a 128*128*63 (0.72*0.72*1.3mm) matrix using ordered subset
expectation maximization techniques. All corrections for attenuation, scatter, deadtime, and randomizations were applied to generate quantifiable images. Computer
outlined region of interest measures (counts per pixel) of the tumor and muscle (at
the symmetric site) were used to determine tumor-to-muscle count density ratios [90].

2.4.25. Kinetic Study of Blood Clearance of 68Ga-GP in New Zealand White Rabbit
New Zealand white rabbits were administered intravenously 2 mCi of 68GaGP. To determine blood clearance and biological half-life of 68Ga-GP, 0.1ml blood
samples were collected from 10 seconds to 20 minutes (14 time points) after injection.
Blood samples were weighed and the radioactivities were counted by a gamma counter.
The radioactivity of each sample was calculated as a percentage of the injected dose per
gram of the blood’s net weight (%ID/g) [90].

2.4.26. Animal Acute Toxicity Studies of GP
Three species (rat, mouse and rabbit) were used to test the acute toxicity of GP.
Rat
48 Fischer-344 rats (Male (24) and Female (24), 195+ 5g) were used. After a 2-day
acclimatization period, rats were placed in cages (3 rats per cage). Following two control
days, rats were administered an intravenous injection (tail vein) of saline and GP (100, 200
and 400 mg/kg) and food intake and body weight were measured daily. The GP was
formulated in saline (0.9%) solution. The injection volume/mouse was 0.3-1.0 ml. Control
groups were administered saline only. Blood chemistry and histopathology (liver, kidney
and heart) were performed on day 3 and 14 following single injection of GP or saline.
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Mouse
To ascertain acute toxicity findings in different species, Swiss Webster mice (male
and female, n=5/gender) were administered GP (1.0 g/kg) and the mice were observed for
14 days. The body weight was obtained every other day.
Rabbit
Acute single-dose toxicity studies were also conducted in a rabbit model. The
rabbits (3 kg body weight) were administered saline or GP at 200 mg/kg, iv. (n=2 per
compound). Blood chemistry was performed at 14 days post-administration.

2.4.27. Scintigraphic Imaging Studies of 99mTc-GP-drug Conjugates
To demonstrate the application of GP chemistry in tumor targeting, two groups of
female Fischer 344 tumor-bearing (right leg) rats were administered with 300 μCi of 99mTclabeled compounds (3 mg). The standard source used for calibration was 30 μCi of
Na99mTcO4. Computer outlined region of interest measures (counts per pixel) of the tumor
and muscle (at the symmetric site) were used to determine tumor-to-muscle count density
ratios. In the first group, the tumor-bearing rats were administered with chitosan (Chi,
control), GP, GP-methotrexate (GP-MTX), GP-folate (GP-FOL), GP-doxorubicin (GPDOX) and GP-pamidronate (GP-PAM).
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2.4.28. In Vitro Cellular Toxicity Assay (MTT assay) of GP-DOX
To determine the cytotoxicity of GP-DOX, MDA-MB-231 cells (7,500/well) were
incubated in a 96-well plate at 37℃overnight. Cells were then treated with GP, DOX or GPDOX at different concentrations (1-500 µg/mL) for 24 to 48 hours. After incubation, 20 µL
of MTT stock solution (5 mg/mL) was added to each well followed by incubation at 37℃for
4 hours. After carefully removing the culture media, 100 µL of DMSO was added to each
well. The 96-well plate was covered by tinfoil and shook on an orbital shaker for 15
minutes. Finally, the absorbances were read at 590 nm with a ELISA reader to determine the
cell viability [99].

2.4.29. In Vitro Cellular Fraction Assay of GP-DOX
To determine the distribution pattern of 99mTc-GP-DOX within the cells, NE-PER
extraction reagents were used for stepwise to isolate cytoplasmic and nuclear extracts from
breast cancer cells. The detailed procedure was described in a previous section (2.4.2).
Briefly, 99mTc-GP-DOX (0.1 mCi) was prepared in the concentration of 0.1 mg/mL. After
20 µl of 99mTc-GP-DOX (0.02 mg/well, 2 µCi) or Na99mTcO4 (control) dispensed into each
well of a 6-well plate and 13762 cells (50,000/well) were incubated at 37℃ for 2 hours.
After incubation, cellular fractions were obtained using NE-PER extraction reagents.
Cellular fraction samples were counted in a gamma counter.
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2.4.30. Scintigraphic Imaging Studies of 99mTc-GP-DOX
To demonstrate the retention of 99mTc-GP-DOX in breast tumor cells, 13762 breast
tumor-bearing rats were administered with 99mTc-GP-DOX (300 µCi/rat, 1.0 mg physical
amount, iv.) Scintigraphic images, using a gamma camera equipped with low-energy,
parallel-hole collimator, were obtained after 2 and 24 hr. The standard source used for
calibration was 30 µCi of Na99mTcO4. Computer outlined region of interest measures
(counts per pixel) of the tumor and muscle (at the symmetric site) were used to determine
tumor-to-muscle count density ratios.

2.4.31. In Vivo Anti-tumor Ability Studies of GP-DOX
MDA-MB-231 cells (3×106 cells/0.1 mL PBS) were inoculated subcutaneously on
the back of nude mice. Tumor size was measured three times a week once tumors reached
around 30mm3. Once tumors reached 250 mm3, different doses of DOX (10 and 20mg/kg),
GP-DOX (100-600mg/kg) and saline (control) were injected intravenously through tail vain.
Tumor sizes were measured carefully until the animal died. Tumor growth delay curves and
survival curves were generated from measured data.

Absolute tumor growth delay in different treatment groups was calculated by using
the time (in days) required for the tumor to grow from 70 to 500 mm3 minus the time
required for control group tumors to reach the same size (70 to 500 mm3).This data was used
to evaluate the efficacy for each agent.
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CHAPTER 3: RADIOLABELED N4amG AS A NUCLEOSIDE TRANSPORTER
TARGETING AGENT FOR TUMOR CELL PROLIFERATION ASSESSMENT

Portions of this work have been published in Tsao N, Chanda M, Yu DF, Kurihara H, Zhang
YH, Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis Biodistribution and Imaging in
Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.
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3.1. Rationale and Study Design
As mentioned in Chapter 1, modern imaging technologies provide non-invasive, high
resolution functional imaging to assess cancer cell proliferation. With proper radiotracers,
both PET and SPECT can be used to evaluate tumor growth potential, determine the degree
of malignancy, and even predict and monitor the treatment responses.

18

F-FDG targets glycolysis pathway. Highly glycolytic areas may generate false

positive results in 18F-FDG-PET imaging. Targeting cell proliferation may overcome these
false positive results because uncontrolled cell proliferation is a distinguishing characteristic
of tumor. Clinical data also supports that nucleoside-based imaging agents will have higher
tumor specificity than 18F-FDG in many cancers [100, 101]. Therefore, radiolabeled N4amG
is anticipated to show high specificity in detecting tumors.

Each synthesized chemical was carefully purified and characterized using NMR,
mass spectrum and HPLC. The radiochemical purity of each radiolabeled compounds were
tested by radio-HPLC and radio-TLC.

To investigate the pharmacology of radiolabeled N4amG, a series of in vitro and in
vivo studies using 13762 cells were conducted. 13762 rat breast adenocarcinoma cells were
used in both in vitro cellular uptake studies and in vivo animal studies because 13762 cells
were well characterized and established in our laboratory.
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An in vitro cellular uptake study using radiolabeled N4amG and its chelator control
was conducted to test the cell penetrating ability of radiolabeled N4amG. Cell sorting
assays, cellular fraction studies and in vitro blocking studies using guanine as a competitive
blocker were conducted to investigate the uptake mechanism.

A biodistribution study using 13762 tumor-bearing rats was used to evaluate the
exact tumor and organ uptake of both radiolabeled

99m

Tc-N4amG and 99mTc-N4 ex vivo. The

distribution of radiotracer in each organ was expressed as percentage of the injected dose per
gram of tissue (%ID/g). Tumor-to-normal tissue count ratios were determined from the
corresponding %ID/g values. The result of the rat biodistribution study was further used to
estimate human radiation absorption dose by using the Olinda software [95], which is a FDA
approved software for human dose estimation.

An in vivo imaging study was conducted to investigate the imaging potential of using
99m

Tc-N4amG as a tumor proliferation marker. Tumor-to-muscle count density ratios were

determined by dividing ROI measures (in counts per pixel) of tumor by ROI measures of the
symmetric normal muscle site. The ratios were used to evaluate the potential of 99mTcN4amG in tumor uptake. In addition, 99mTc-N4amG was used to image tumor-bearing rats
before and after paclitaxel treatment. This study was used to evaluate the treatment
monitoring ability of 99mTc-N4amG. Furthermore, inflammation and tumor dual-bearing rats
were used to investigate the tumor specificity of 99mTc-N4amG. To determine the important
pharmacological factor, biological half-life of 99mTc-N4amG in blood, a blood clearance
study was also performed.
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To further investigate the correlation between 99mTc-N4amG tumor uptake and tumor
cell proliferation, immunohistochemistry analysis using Ki-67 as a cellular proliferation
marker in tumor-bearing rats was conducted. Adequate tumor samples were surgically
removed. Biopsy tumor samples were then formalin-fixed, paraffin-embedded and cut into
4μm sections in a standard manner. Tumor sections were immunohistochemically stained by
anti-Ki67 mouse monoclonal antibody.

For the statistical analysis, the percent of injected dose per gram of tissue weight
(%ID/g) and tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as
mean ± S.D. The uptakes of 99mTc-N4amG and control tracer were compared using a
Student’s t-test. Differences were considered to be statistically significant for a two-tailed
p<0.05.
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3.2. Results
3.2.1. Chemistry and Radiochemistry
3.2.1.1. Synthesis of 9-[4-amino-3-(hydroxymethyl)butyl]guanine (NH2-Guan, compound I)
NH2-Guan was synthesized through a 4-step reaction route. Briefly, the amino
functional group and one of the hydroxyl functional groups of penciclovir were selectively
protected by methoxytrityl protection group. The protected penciclovir was reacted with ptoluene sulfonyl chloride to convert the unprotected hydroxyl group to a tosyl group. The
tosylated penciclovir was reacted with sodium azide to form the azido penciclovir. The
crude azido penciclovir was then dissolved in anhydrous tetrahydrofuran and
triphenylphosphine was added to reduce azido to amino penciclovir. Finally, hydrochloric
acid was added to de-protect all the functional groups. After Sephadex-G15 column
purification, the desired product (NH2-Guan) was obtained. Ninhydrin (2% in methanol)
spray test demonstrated the presence of amino group. Proton and 13C NMR were performed.
1

H NMR (CDCl3): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m, 2H), 2.90 (d, 2H, J

= 6.0 Hz), 1.72 (m, 2H), 1.43 (m, 1H). FAB MS: 253 [M + H] + (Figures 1-4).
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Figure 1. HPLC analysis of NH2-Guan.
The retention time of NH2-Guan was 10.12 minutes.
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Figure 2. Mass spectrum analysis of NH2-Guan.
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Figure 3. Proton NMR analysis of NH2-Guan
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Figure 4. 13C NMR analysis of NH2-Guan.
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3.2.1.2. Synthesis of Cyclam-(BOC)3-AA
Cyclam-(BOC)3-AA was synthesized through a 3-step reaction route. Briefly,
1,4,8,11-tetraazacyclotetradecane (cyclam) was dissolved in methylene chloride. Three of its
four amino groups were selectively protected with boc protection groups to form cyclam(BOC)3. Cyclam-(BOC)3 was dissolved in DMF and reacted with ethyl bromo acetate to
form cyclam-(BOC)3-EA. Cyclam-(BOC)3-EA was then de-protected under base conditions
to obtain cyclam-(BOC)3-AA. Proton NMR and mass spectrometry analyses were
conducted. 1H NMR (CDCl3): δ 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.81 (m, 2H), 2.55 (m,
2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for C 27H51N4O8 [M +
H] + 559.3629 found 559.5141 (Figures 5 and 6).
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Figure 5. Proton NMR analysis of cyclam-(BOC)3-AA.
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Figure 6. Mass spectrum analysis of cyclam-(BOC)3-AA.

54

3.2.1.3. Synthesis of Cyclam Mono acid-9-[4-amino-3-(hydroxymethyl)butyl]guanine
Conjugate (N4amG)
Cyclam-(BOC)3-AA was reacted with NH2-Guan under water conditions (Figure 7).
At the presence of sulfo-NHS and EDC, an amide linkage was formed between the
carboxylic acid of cyclam-(BOC)3-AA and the amino group of NH2-Guan. After de-boc and
dialysis, the desired product (N4amG) was obtained. Mass spectronmetry and HPLC
analysis were performed. 1H NMR (D2O): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61
(m, 2H), 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.90 (d, 2H, J = 6.0 Hz), 2.81 (m, 2H), 2.55 (m,
2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.67 (m, 2H), 1.43 (m, 1H). Exact mass calculated for
C22H41N10O3 (N4amG) [M + H] + was 493.3358 found 493.3340 (Figure 8). HPLC
spectra showed that the purity of N4amG was greater than 95% (Figure 9). After NMR
confirmation (Figure 10), the impurity (<5%, retention time: 14.915 min) was protected
precursor.
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Figure 7. Schematic of N4amG synthesis.
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG:
Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.
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Exact Mass: 492.3285
Mol. Wt.: 492.6182
m/e: 492.3285 (100.0%), 493.3318 (23.8%), 493.3255 (3.7%), 494.3352 (2.7%)
C, 53.64; H, 8.18; N, 28.43; O, 9.74

Figure 8. Mass spectrum analysis of N4amG.
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG:
Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.
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Figure 9. HPLC analysis of N4amG.
The spectra showed that the purity of N4amG was greater than 97%. Reprinted with permission from Tsao N, Chanda M, Yu DF,
Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis Biodistribution and Imaging in Breast Tumor-bearing
Rodents. Applied Radiation and Isotopes 72: 105-113.
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Figure 10. Proton NMR analysis of N4amG.
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3.2.1.8. Radiolabeling of N4amG with99mTc
N4amG (5 mg) was dissolved in 0.2 ml distilled water. Subsequently, 0.1 mL Tin
(II) chloride solution (1 mg in 1 ml of water) and sodium pertechnetate (Na 99mTcO4, 1.0
mCi, Mallinckrodt, Houston, TX) were added sequentially. The total volume was adjusted to
1.0 mL by adding adequate amount of distilled water. The reaction mixture was kept at room
temperature for 10 minutes. The specific activity was 5 mg/1 mCi/ml. Radiochemical purity
was determined by ITLC eluted with saline. From radio-TLC analysis (Bioscan,
Washington, DC) and HPLC analysis (Waters, Milford, MA), the radiochemical purity was
more than 95% (Figure 11).
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Figure 11. Radio-HPLC analysis of 99mTc-N4amG.
The spectra showed that the radiochemical purity of 99mTc-N4amG was greater than 95%.
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH,
Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis Biodistribution and Imaging in Breast
Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.
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3.2.1.9. Synthesis of 9-[4-bromo-3-(hydroxymethyl) butyl]guanine (Bromo-Guan)
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 170.25 mg, 0.75 mmol),
triphenylphosphine (196.72 mg, 0.75 mmol) and tetrabutylammonium bromide (241.79 mg,
0.75 mmol) was dissolved in 20mL anhydrous dichloromethane. The reaction mixture was
stirred for 5 minutes at room temperature and then tritylated penciclovir (0.5 g, 0.625 mmol)
was added and stirred for 3 hours. The solvent was rotary evaporated and the crude product
was column purified with 1-5% methanol in dichloromethane as mobile phase. Exact mass
calculated was 316.03 found 316.4 (Figures12-15).
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Figure 12. Mass spectrum analysis of Bromo-Guan.
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Figure 13. HPLC analysis of Bromo-Guan.
The retention time of Bromo-Guan was 5.69 minutes whereas the retention time of
penciclovir was 4.88 min.
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Figure 14. Proton NMR analysis of Bromo-Guan.
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Figure 15. 13C NMR analysis of Bromo-Guan.

66

3.2.1.10. Synthesis of N2-(p-anisyldiphenylmethyl)-9-[(4-iodo)-3-panisyldiphenylmethoxymethylbutyl]guanine (Iodo-Guan-dt)
N2-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-panisyldiphenylmethoxymethylbutyl]guanine (190 mg, 0.2 mmol) was placed in a dry round
bottom flask. 40 mL of acetone and potassium iodine (996 mg, 16.0 mmol) was added. The
reaction mixture was stirred at 55℃ for 16 hours. The reaction mixture was cooled to room
temperature, and was evaporated by a rotary evaporator. The crude product was re-dissolved
in 40 mL dichloromethane and water washed. The aqueous phase was extracted with
dichloromethane. The combined organic phase was dried with anhydrous MgSO 4 and
evaporated to yield the crude product. 129 mg of the crude iodo compound was obtained.
Exact mass calculated for C50H46IN5O4 [M + H] + 908.2594 found 908.2670 (Figure 16).
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Figure 16. Mass spectrum analysis of Iodo-Guan-dt.

68

3.2.1.11. Synthesis of 1,5,8,12-tetraazabicyclohexadecane-13, 14-dione (N4-Oxalate)
1,4,8,11-tetraazacyclotetradecane (cyclam) (15.00 g; 74.88 mmol) was dissolved in
150 mL of ethanol anhydrous ethanol, and diethyl oxalate (10.94 g; 74.88 mmol) was added.
The reaction mixture was refluxed 18 hours at 75℃. The solvent was rotary evaporated and
the crude product was re-crystallized in acetone to yield white crystals. Yield: 13.64 g
(17.31 mmol; 72%). 1H NMR (CDCl3) δ=4.35 (m, 2H), 3.75 (m, 2H), 3.40 (m, 2H), 2.77 (m,
2H), 2.68 (m, 2H), 2.54 (m, 2H), 2.43 (m, 4H), 1.75 (m, 2H), 1.24 (m, 2H). 13C NMR δ=
158.55, 49.92, 49.38, 47.73, 44.13, 25.42 (Figure 17). MS: m/z = 255.33[M] +.
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Figure 17. 13C NMR analysis of N4-Oxalate.
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3.2.1.12. Attempt to Synthesize N4-Guan
Many efforts have been made to synthesize N4-Guan from Bromo-Guan or IodoGuan with N4 or N4-Oxalate (Table 1). After TLC, NMR and mass spectrum analysis, none
of these attempts had successfully obtained N4-Guan.

Table 1. Different reaction conditions used to synthesize N4-Guan

Starting
Materials

Solvent

Base

Conditions

N4-Oxa

DMF

Triethylamine

90°C, 16hr

N4

DMF

-

85°C, 16hr

DMF

-

1. 75°C, 16hr

(Br-G-dt/Br-G +)

N4-Oxa
O
N

HN

N

HN

2. 65°C, 48hr

O

N4

N4-Oxa

Ethanol, H2O
NH

HN

NH

HN

1. K2CO3
2. NaOH

Acetonitrile

K2CO3

N4
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70°C, ~48hr
pH=9-10
65°C, 48hr

3.2.1.13. Attempt to Synthesize EC-Guan
Only 5.2mg of EC-Guan has been gained from 6 gram of penciclovir. The yield was
<1%. Proton NMR was conducted to confirm the structure (Figure 18).

1.0 mg of EC-Guan was used to label with 99mTc-NaTcO4 in a standard manner.
Radio-HPLC was used to analyze the radiochemical purity. The retention time of 99mTc-ECGuan (5.3 minutes) was different and longer than 99mTc-EC (4.6 minutes) (Figure 19). The
finding indicated that EC-Guan was successfully synthesized and had high chelating ability.
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Figure 18. Proton NMR analysis of EC-Guan.
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Figure 19. Radio-HPLC analysis of 99mTc-EC and 99mTc-EC-Guan.
The longer retention time of 99mTc-EC-Guan (5.3 minutes) indicated the higher hydrophobic
properties than 99mTc-EC.
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3.2.2. Pharmacology and Toxicology
3.2.2.1. In vitro cellular uptake assay
To evaluate whether 99mTc-N4amG can penetrate the cell membrane, an in vitro
cellular uptake study using 99mTc-N4amG and its chelator control (99mTc-N4) was
conducted. High cellular uptake (up to 17%ID at 4 hour) of 99mTc-N4amG in breast tumor
cells was observed in a cellular uptake study (Figure 20). The accumulation increased with
increase in incubation time suggesting 99mTc-N4amG has tumor targeting potential.
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Figure 20. In vitro cellular uptake of 99mTc-N4amG.
13762 rat breast tumor cells (50,000 per each well) were incubated with 2 µCi of 99mTcN4amG at 37℃ at 0.5-4 hours. There was a gradually increased uptake of 99mTc-N4amG in
mammary tumor cells. Data are expressed in mean ± S.D. percent of incubation dose from
three measurements. Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara
H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis Biodistribution and
Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.
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3.2.2.2. In Vitro Cellular Fraction Assay
To determine the distribution pattern of 99mTc-N4amG within the cells, NE–PER
extraction reagents were used stepwise to isolate cytoplasmic and nuclear extracts from
13762 rat breast cancer cells. Nucleus fraction had 40% uptake of 99mTc-N4amG whereas
cytosolic fraction had 60%. Both nucleus and cytosolic fractions in 99mTc-N4amG were
higher than 99mTc-N4 (Figure 21). The data indicated that 99mTc-N4amG, but not 99mTc-N4,
could penetrate the cell membrane, and about 40% of 99mTc-N4amG was accumulated in the
cell nucleus.
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Figure 21. In vitro cellular fractions of 99mTc-N4amG.
After 2 ml of radioactive media containing 2 µCi (0.074 MBq) of 99mTc-N4amG (0.02
mg/well) or 99mTc-N4 (control) was dispensed into each well of a 6-well plate, cellular
fractions were isolated by using an NE-PER extraction kit. Nucleus fraction had 40% uptake
of 99mTc-N4amG, whereas cytosolic fraction had 60%. Both nucleus and cytosolic fractions
in 99mTc-N4amG were higher than 99mTc-N4. Data were expressed in mean ± S.D. percent of
incubation dose from three measurements. Reprinted with permission from Tsao N, Chanda
M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis
Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and
Isotopes 72: 105-113.
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3.2.2.3. In Vitro Cellular Blocking Assay
To determine whether cellular uptake of 99mTc-N4amG was via nucleoside
transporter, guanine was used as competitive blocker to perform the cellular blocking assay.
There was decreased uptake in cells treated with guanine but not with glucose (Figure 22).
The results suggested that cellular uptake of 99mTc-N4amG was via nucleoside transporters.
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Figure 22. In vitro cellular blocking assay of 99mTc-N4amG.
13762 rat breast tumor cells were incubated with guanine (specific) or glucose at 0.25-1.0
mg/well for 30 minutes, followed by 99mTc-N4amG (4 µCi/well, 0.02 mg/well). The cells
were incubated for additional 20 minutes. Data were expressed in mean ± S.D. percent of
incubation dose from three measurements.
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3.2.2.4. In Vitro Cellular Sorting Assay
To further investigate whether different cell cycle phases have different capacity in
the uptake of 99mTc-N4amG, a cell sorting assay was conducted. Cells in S phase showed
highest uptake of 99mTc-N4amG followed by G2/M phase (Figure 23). Compared to
chelator-only control (99mTc-N4), 99mTc-N4-Guan showed greater uptake in each cell cycle
phases. These data suggested 99mTc-N4amG was a cell cycle S phase-specific radiotracer.
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Figure 23. In vitro cell sorting assay of 99mTc-N4amG.
Cells were sorted into the various phases of cell cycle (G0/G1, S, and G2/M) using
fluorescence activated cell sorter. Sorted cells were suspended in 15mL test tubes (50,000
cells/ tube). 99mTc-N4-Guan or 99mTc-N4 was added, and the cells were incubated at 37 ℃
for 60 min. Following the incubation period, cells were centrifuged and washed with PBS
twice. After final centrifugation, radioactivity was measured by gamma counter. Data were
processed and presented as mean ± S.D. Reprinted with permission from Tsao N, Chanda
M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTc-N4amG: Synthesis
Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and
Isotopes 72: 105-113.
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3.2.2.5. Biodistribution Studies
In biodistribution studies, there was an increased uptake in tumor-to-blood and
tumor-to-muscle ratios in breast tumor-bearing rats. The optimum tumor uptake and tumorto-muscle ratios were obtained 2–4 hours post-administrations. There was no increased
uptake in thyroid and stomach suggesting in vivo stability of 99mTc-N4amG (Tables 2 and 3).
99m

Tc-N4amG was excreted through liver and kidneys. Relatively high uptake in bone and

spleen was observed, suggesting 99mTc-N4amG could target organs with high proliferation
properties.

99m

Tc-MIBI biodistribution using 13762 tumor-bearing rats (Table 4) showed similar

main organs uptake with the published data (Table 5) [102]. 99mTc-MIBI washed out from
blood quickly and accumulated in heart. The heart-to-blood count ratios reached 42.02 at 30
minutes after injection. Compared to 99mTc-MIBI, 99mTc-N4amG showed longer blood
retention and higher liver, tumor, spleen and bone uptake.
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Table 2. Biodistribution of 99Tc-N4 in breast tumor-bearing rats
______________________________________________________________________________
% of injected dose per gram of tissue weight (n=3/time, interval, iv)
0.5 HR

2 HR

4 HR

BLOOD

0.23 ±0.009

0.04 ±0.002

0.02 ±0.002

HEART

0.07 ±0.005

0.01 ±0.001

0.01 ±0.000

LUNG

0.20 ±0.011

0.05 ±0.002

0.03 ±0.001

THYROID

0.25 ±0.011

0.03 ±0.002

0.02 ±0.001

PANCREAS

0.07 ±0.007

0.02 ±0.002

0.02 ±0.001

LIVER

2.98 ±0.083

1.14 ±0.018

0.79 ±0.026

SPLEEN

0.35 ±0.026

0.37 ±0.007

0.39 ±0.020

KIDNEY

2.56 ±0.101

1.11 ±0.045

0.65 ±0.028

STOMACH

0.12 ±0.005

0.02 ±0.001

0.01 ±0.000

INTESTINE

0.25 ±0.004

0.39 ±0.048

0.14 ±0.003

UTERUS

0.16 ±0.014

0.02 ±0.001

0.01 ±0.001

TUMOR

0.09 ±0.004

0.03 ±0.003

0.02 ±0.001

MUSCLE

0.05 ±0.002

0.01 ±0.000

0.01 ±0.000

BONE

0.07 ±0.001

0.02 ±0.001

0.01 ±0.000

BRAIN

0.01 ±0.000

0.00 ±0.000

0.00 ±0.000

TUMOR/BLOOD

0.40 ±0.002

0.78 ±0.044

0.70 ±±0.008

TUMOR/MUSCLE

1.96 ±0.015

5.32 ±0.402

3.35 ±0.147

TUMOR/BRAIN

6.19 ±0.365

11.06 ±0.667

11.93 ±0.675

______________________________________________________________________________
Value shown represents the mean  standard deviation of data from 3 animals
[Applied Radiation and Isotopes 2013; 72: 105-113]
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Table 3. Biodistribution of 99Tc-N4amG in breast tumor-bearing rats
______________________________________________________________________________
% of injected dose per gram of tissue weight (n=3/time, interval, iv)
0.5 HR

2 HR

4 HR

BLOOD

1.47 +0.03

0.91 +0.12

0.61 +0.09

HEART

0.41 +0.06

0.25 +0.03

0.17 +0.03

LUNG

0.88 +0.13

0.61 +0.14

0.42 +0.08

THYROID

0.67 +0.02

0.51 +0.06

0.38 +0.09

PANCREAS

0.29 +0.03

0.19 +0.04

0.13 +0.01

LIVER

8.39 +2.26

8.07 +0.28

8.25 +1.30

SPLEEN

1.08 +0.16

1.12 +0.21

1.18 +0.15

KIDNEY

4.30 +0.57

6.71 +0.53

7.06 +1.04

STOMACH

0.37 +0.05

0.30 +0.05

0.24 +0.02

INTESTINE

0.35 +0.04

0.24 +0.04

0.21 +0.07

UTERUS

0.48 +0.02

0.31 +0.06

0.22 +0.04

TUMOR

0.43 +0.04

0.37 +0.06

0.32 +0.06

MUSCLE

0.13 +0.03

0.11 +0.01

0.07 +0.02

BONE

0.96 +0.07

0.82 +0.36

1.02 +0.21

BRAIN

0.04 +0.01

0.02 +0.00

0.02 +0.01

T/BLOOD

0.29 +0.02

0.41 +0.03

0.52 +0.02

T/MUSCLE

3.24 +0.38

3.49 +0.41

4.30 +0.59

________________________________________________________________________________
Value shown represent the mean  standard deviation of data from 3 animals
[Applied Radiation and Isotopes 2013; 72: 105-113]
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Table 4. Biodistribution of 99Tc-MIBI in breast tumor-bearing rats

% of injected dose per gram of tissue weight (n=3/time, interval, iv)

Blood
Heart
Lung
Thyroid
Pancreas
Liver
Spleen
Kidney
Stomach
Intestine
Uterus
Tumor
Muscle
Bone
Brain
T/Blood
T/Muscle

15 MIN
MEAN SEM
0.01
0.15
0.27
4.30
0.13
1.41
0.20
2.06
0.12
3.56
0.11
1.91
0.09
1.91
0.71
7.43
0.17
2.76
0.10
1.72
0.05
0.68
0.03
0.61
0.02
0.54
0.03
0.53
0.00
0.04
0.01
4.07
0.01
1.13

45 MIN
MEAN SEM
0.00
0.05
0.31
3.69
0.07
0.63
0.08
1.45
0.18
1.99
0.02
0.83
0.05
0.91
0.34
4.25
0.10
1.80
0.07
0.95
0.02
0.48
0.02
0.37
0.02
0.63
0.03
0.35
0.00
0.02
0.02
7.40
0.00
0.59

2 HR
MEAN SEM
0.00
0.03
0.14
3.60
0.02
0.34
0.07
1.06
0.04
0.87
0.05
0.33
0.02
0.58
0.21
2.28
0.05
1.50
0.11
0.77
0.01
0.35
0.03
0.24
0.06
0.59
0.01
0.25
0.00
0.01
0.02
8.00
0.02
0.41

Value shown represent the mean  SEM of data from 3 animals
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4 HR
MEAN SEM
0.00
0.02
0.05
3.48
0.02
0.23
0.03
0.94
0.05
0.41
0.01
0.33
0.03
0.35
0.10
1.73
0.13
1.37
0.04
0.45
0.03
0.29
0.02
0.21
0.03
0.57
0.01
0.15
0.00
0.01
0.01
10.50
0.01
0.37

Table 5. Biodistribution of 99Tc-MIBI in rat
% of injected dose per gram of tissue weight (n=3/time, interval, iv)
5 MIN

30 MIN

BLOOD

0.12 +0.01

0.04 +0.01

HEART

1.50 +0.02

1.61 +0.18

LUNG

0.92 +0.04

0.49 +0.00

LIVER

0.94 +0.03

0.83 +0.11

SPLEEN

1.55 +0.06

1.09 +0.05

KIDNEY

6.53 +0.19

2.38 +0.34

BRAIN

0.03 +0.01

0.03 +0.01

HEART/BLOOD

12.78

42.02

HEART/LUNG

1.68

3.27

_____________________________________________________________
Value shown represent the mean  standard deviation of data from 3 animals
[Nuclear Medicine and Biology 1995; 22: 585-588]
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3.2.2.6. Olinda Dosimetry Estimation
The human residence time estimates were applied to the Olinda software to produce
radiation dose estimates for 99mTc-N4amG. The Olinda output was multiplied by a proposed
human dose of 20 mCi for 99mTc-N4amG to yield total absorbed dose from an imaging study
(Table 6). Radiation exposure to the whole body, blood forming organs (red marrow,
spleen), gonads (testes, ovaries), and effective dose equivalent for the proposed human
single dose at 20 mCi fall below the limits of 3 rad annually and 5 rad total. The absorbed
dose in all other organs (e.g., kidneys) was below the limits of single dose of 5 rad annually
and 15 rad in total. 99mTc-N4amG showed total rad absorbed by each organ was below the
proposed annual and total limits. Compared to the radiation dosimetry of 99mTc-MIBI (Table
7) [103], 99mTc-N4amG showed lower overall radiation absorption (effective dose: 1
rem/mCi = 0.27 mSv/MBq).
.
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Table 6. Radiation dose estimates of the reference adult for 99Tc-N4amG
Organs (5 rem annual/15 rem total)
target organ

rad/mCi

human dose (20mCi)

Adrenals

1.01E-02

0.202

Brain

8.52E-04

0.017

Breasts

2.09E-03

0.042

Gall bladder wall

1.03E-02

0.206

LLI wall

9.35E-04

0.019

Small int

3.56E-03

0.071

Stomach

7.11E-03

0.142

ULI wall

3.53E-03

0.071

Heart wall

1.66E-02

0.332

Kidneys

7.60E-02

1.520

Liver

2.83E-02

0.566

Lungs

1.55E-02

0.310

Muscle

2.15E-03

0.043

Pancreas

1.23E-02

0.246

Bone surfaces

1.19E-02

0.238

Skin

9.45E-04

0.019

Testes

1.86E-04

0.004

Thymus

3.30E-03

0.066

Thyroid

7.62E-04

0.015

Urine bladder wall

4.18E-04

0.008

Uterus

1.06E-03

0.021

EFF dose

6.79E-03

0.136

Blood-forming organs (3 rem annual/ 5 rem
total)
target organ
rad/mCi

human dose (20mCi)

Ovaries

1.24E-03

0.025

Red marrow

3.07E-03

0.061

Spleen

5.45E-02

1.090

EFF dose equivalent

1.45E-02

0.290

Total body

3.73E-03

0.075

[Applied Radiation and Isotopes 2013; 72: 105-113]
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Table 7. Radiation dosimetry for 99Tc-MIBI in adults

ICRP: International Commission on Radiological Protection
RIDIC: Radiation Internal Dose Information Center
[Journal of Nuclear Medicine 2008; 49:1555–1563]

90

3.2.2.7. Scintigraphic Imaging Studies
In planar imaging studies, the tumors could be well visualized in 13762 breast
tumor-bearing rats (Figure 24). From computer outlined region of interest analysis, the
average tumor-to-muscle count density ratios (n=3 rats) at 1, 2 and 4 hr were 3.69±0.15,
3.96±0.52 and 4.93±0.79, respectively. There was a gradually linear increased tumor-tomuscle count density ratio (p<0.1, compared to 1 hour T/M ratio) indicating the tumor
targeting potential of 99mTc-N4amG.
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Figure 24. Planar scintigraphy of 99mTc-N4amG in breast tumor-bearing rats at 1-4 hours.
The numbers indicate tumor-to-muscle ratios (counts/pixel). Data showed that 99mTcN4amG could gradually accumulate inside tumor (p<0.1). Reprinted with permission from
Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 99mTcN4amG: Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied
Radiation and Isotopes 72: 105-113.
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3.2.2.8. Scintigraphic Imaging Studies Pre- and Post- Treatment
To demonstrate the application of 99mTc-N4amG in monitoring treatment response,
three 13762 breast tumor-bearing rats were administered with 99mTc-N4amG at pre- and
post-paclitaxel treatment at 48 hours. In images, the tumors could be well visualized in
breast tumor-bearing rats. From computer outlined region of interest analysis, the average
tumor-to-muscle count density ratios at 1 and 4 hour was 3.69±0.15and 4.93±0.79 (before
paclitaxel therapy) and changed to 1.68±0.13 and 2.21±0.68 (post-paclitaxel therapy).

There was decreased tumor-to-muscle count density ratios (p<0.01, avg. 45-72%)
post-paclitaxel treatment determined by 99mTc-N4amG at 1-4 hour. We previously have
reported that the timing of apoptosis occurred at earlier time interval on day 2-3 post-paclitaxel
treatment [96], which was supported by histopathology. Though the decrease in radionuclide
retention from tumor-to-muscle count density ratios before and after paclitaxel treatment is
minimal, this might be due to apoptosis occurred at earlier time. This data indicated the
treatment monitoring ability of 99mTc-N4amG (Figure 25).
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Figure 25. Planar images of 99mTc-N4amG at pre- and 72 hour post-treatment with
paclitaxel (20 mg/kg, iv.).
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3.2.2.9. Scintigraphic Imaging Studies Tumor/Inflammation Animal Model
To demonstrate differential diagnosis of 99mTc-N4amG between tumor and
inflammation, the left legs of 13762 breast tumor-bearing rats were bearing with turpentineinduced inflammation. The average tumor-to-inflammation count density ratio reached 1.90
± 0.39 at 4 hours imaging (Figure 26).
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Figure 26. Comparison of tumor-to-muscle and inflammation-to-muscle ratios using 13762
breast tumor-bearing rats with inflammation.
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3.2.2.10. Ki-67 Staining
Ki-67 staining showed more than 80% Ki-67 positive cells in 13762 tumors. After 48
hours paclitaxel (60mg/kg, iv., single injection) treatment, tumors were shrinking and Ki-67
showed less than 20% positive cells (Figure 27). The correlation between Ki-67 staining and
99m

Tc-N4amG uptake suggested that 99mTc-N4amG could be used as a proliferation marker.
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Figure 27. H&E and Ki-67 staining of tumor samples, pre- and post-treatment with
paclitaxel.
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3.2.2.11. Kinetic Study of Blood Clearance of 99mTc-N4amG in Rats
To determine blood clearance and biological half-life of 99mTc-N4amG, Fischer-344
rats were administered 99mTc-N4amG. The blood clearance of 99mTc-N4amG showed both
distribution phase and elimination phase (Figure 28). The elimination phase was used to
calculate the biological half-life (t1/2) of 99mTc-N4amG. Regression line formulation (y=0.0078x+1.1329, R² = 0.9145) was estimated using Microsoft Office Excel 2003. The
biological t1/2 of 99mTc-N4amG was 63.72 minutes.
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Figure 28. 99mTc-N4amG blood clearance in rat.
The biological t1/2 of 99mTc-N4amG was 63.72 minutes.
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3.2.2.12. Radiolabeling of N4amG with 68Ga
Radio-HPLC data showed the radiochemical purity of 68Ga-N4amG was greater than
95%. There was no impurity observed in the spectrum (Figure 29).
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Figure 29. Radio-HPLC analysis of 68Ga-N4amG.
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3.2.2.13. In Vitro Cell Culture Assay
To evaluate whether 68Ga-N4amG can penetrate the cell membrane, an in vitro
cellular uptake study using 68Ga-N4amG and its chelator control (68Ga-N4) was conducted.
High cellular uptake (up to 5.8%ID at 4 hour) of 99mTc-N4amG in 13762 rat breast tumor
cells was observed (Figure 30). The accumulation increased as a function of time suggesting
68

Ga-N4amG has tumor targeting potential.
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Figure 30. Cellular uptake of 68Ga-N4amG.
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4

3.3. Discussion
N4amG was synthesized through a 9-step synthetic route. The overall synthetic yield
of N4amG was 6%. There were two low-yield steps involved in the synthetic route. The first
low-yield step was in the very first synthetic step. As mentioned earlier, the hydroxyl group
is crucial for the phosphorylation of N4amG. The phosphorylated N4amG is trapped inside
the cell and involves in the DNA synthesis. Thus, one of the hydroxyl groups must be
preserved during the synthesis. In other words, selectively protecting one of these two
symmetric hydroxyl groups was necessary in the first step. Taking the advantage of the
spatial blocking effect, a bulky protection group, methoxytrityl group, was chosen in the
first stop to selectively protect one of the two hydroxyl groups. Unfortunately, this strategy
caused low yield because single protected product (desired product) and double protected
product (impurity) were competitive with each other. Longer reaction time favors the double
protected product; meanwhile, shorter reaction time results in a large amount of non-reacted
starting materials. The yield of the first step was about 40%. The impurities were mainly
non-reacted penciclovir and double protected compounds. The second low-yield step was
tosylation (the second step). The yield of tosylation of alcohol is usually around 50%.
Considering there was a bulky methoxytrityl group beside the hydroxyl group; the spatial
blocking effect would reduce the reaction yield to 34%. The rest of the steps gave pretty
good yield from 75%-95%.

Many efforts have been made to synthesize direct linkage of N4-Guan (with carbonnitrogen linkage not amide linkage) from Bromo-Guan/Iodo-Guan with N4/N4-Oxalate. At
least three different solvent systems (DMF, ethanol/H2O and acetonitrile), three different
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bases (triethylamine in DMF, potassium carbonate and sodium hydroxide in ethanol/H 2O
and acetonitrile) and many other reaction conditions, including temperature, pH value and
reaction time, have been tested. Unfortunately, none of these attempts worked. EC was then
used to substitute N4 as the chelator for the reaction. EC-Guan was successfully synthesized
under ethanol/H2O conditions in the presence of potassium carbonate. However, only 5.2 mg
of EC-Guan was gained from 6 gram of penciclovir. The yield of EC-Guan was less than 1%.
The reaction is a SN2 reaction, also known as bimolecular nucleophilic substitution. During
the reaction, an intermediate of N4 (or EC) and Bromo-Guan forms before the leaving group
(Br-) left. Formation of an intermediate is crucial in SN2 reactions. In my reaction,
unfortunately, the bulky methoxytrityl group was located close enough to inhibit the
formation of the intermediate. In other words, the reaction was not favorable because of the
spatial blocking effect caused by the bulky protection group. There was an alternative. If the
de-protection was performed before the reaction, there would be no spatial blocking effect.
Nevertheless, unprotected Bromo-Guan could undergo an intermolecular SN2 reaction using
its own unprotected hydroxyl group or amino group to eliminate its bromine. Since
intermolecular reaction is much faster than intramolecular reaction, the yield of desired
compound is anticipated to be poor.

It is crucial for a radiotracer to penetrate the cell membrane and accumulate inside
the cell in order to properly image proliferating cells. In the in vitro cellular studies, results
showed 99mTc-N4amG penetrated the cell membrane and accumulated inside the cell in a
gradually increased manner. The uptake %ID reached 9 after three hours of incubation and
17 after four hours. Inside cells, about 40% intracellular 99mTc-N4amG was located in the
106

nucleus. In addition, guanine, but not glucose, could significantly block the cellular uptake
of 99mTc-N4amG. It is known that penciclovir can penetrate the cell membrane through
hNTs. Furthermore, inside cells, phosphorylated penciclovir can be recognized as dGMP
and thereby involved in DNA synthesis [54]. With the same nucleoside backbone, 99mTcN4amG may work very similarly to penciclovir inside cells. These results indicated that
99m

Tc-N4amG could penetrate the cell membrane through NTs [54], and involve in nucleus

activity. Various nucleoside drugs, including penciclovir, fludarabine and gemcitabine, have
all been proven to enter cells via NTs [54, 104]. Furthermore, Paproski, et al. demonstrated
NTs play important role in mediating 18F-FLT uptake both in vitro and in vivo [36, 37].
Therefore, 99mTc-N4amG can penetrate cell membrane most likely through nucleoside
transporters.

Two human protein families have been identified in uptake of nucleosides: human
Equilibrative Nucleoside Transporter proteins (hENTs) and human Concentrative
Nucleoside Transporter proteins (hCNTs). hENTs are sodium-independent, facilitated
diffusion bidirectional carriers and consist of four members (ENT1-4) [105]. hCNTs are
sodium-dependent, unidirectional active transporters and consist of three members (CNT13) [106]. In hENTs, hENT1 and hENT2 are well-characterized transporters. Both have
broad tissue distribution and wide range of transporting nucleosides (Table 8), including
both purines and pyrimidines [107, 108]. It is also known that higher abundance of hENT1
protein expression is associated with higher proliferation rate [109, 110]. hENT3 and
hENT4 are two new members of hENTs. hENT3 is a lysosomal transporter working in a
pH-dependent manner with the optimal pH value of 5.5 [111]. In addition, hENT3 has broad
107

substrate selectivity but is relatively insensitive. Similarly, hENT4 can transport adenosine
in acidic condition with low sensitivity [112]. Compared with hENTs, hCNTs have higher
affinity with their substrates and are also more selective in terms of substrates [105]. hCNT1
prefers pyrimidine nucleosides, and hCNT2 prefers purine nucleosides [113]. hCNT3
translocates both purine and pyrimidine nucleosides. Furthermore, hCNTs are very abundant
in specialized epithelial tissues including liver, kidney and intestine [114-116]. hCNT2 are
widespread in brain, whereas hCNT1 and hCNT3 are limited in some regions of brain [117].
Since most hNTs are widespread among tissues, and the substrates selectivity is low, hNTspecific inhibitors such as dilazep, which inhibits hENT1 and hENT2, and NBMPR, which
inhibits only hENT, can be used to identify the roles of different subtype of hNTs in
nucleoside analogues uptake [118].
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Table 8. Tissue and cellular distribution of nucleoside transporters.
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In a cell sorting assay, the ideal way to perform this study is to incubate cells with
radiotracers and then sort cells into different cell cycle phases. After sorting, one counts the
activity of each stage of cells to obtain the correlation between cell uptake and cell cycle
stages. However, to avoid radiation contamination of the FACS machine, it is prohibited to
sort cells after radiotracer incubation. Therefore, the second best way to conduct this study is
to sort cells first and then incubate radiotracers with these already sorted cells in suspension
condition. The suspended cells may not perform exactly as they do when they are attached.
This is a technical limitation that is difficult to overcome. Even so, the results from this
study can still provide an idea that 99mTc-N4amG is an S phase-preferred agent. This uptake
pattern is also found in many nucleoside-based chemotherapy agents [119].

In animal studies, biodistribution results showed relatively high uptake in bone and
spleen (1.02±0.21 and 1.18±0.15 %ID per gram of tissue weight at 4 hour, respectively.) As
bone marrow and spleen are both blood forming organs, it suggests that 99mTc-N4amG can
target highly proliferating cells. Furthermore, as an imaging agent, in vivo imaging will be
the ultimate method to evaluate its feasibility for clinical applications. Our animal imaging
studies showed that 99mTc-N4amG can actively accumulate in tumor. The tumor-to-muscle
ratio increased as a function of time. It reached 4.93±0.79 at 4 hour after injection. 99mTcN4amG can also monitor treatment outcome because it could differentiate tumor from
inflammation and it was highly correlated to proliferation marker, Ki-67. These animal
study results along with in vitro cell culture data suggest that 99mTc-N4amG is a potential
cell proliferation marker for future malignant diseases assessment.
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In conclusion, N4amG, a novel nucleoside-based imaging tracer, can target tumor
cell proliferation, for which good imaging agents are currently not available. The results
demonstrated that N4amG can be synthesized in an appropriate yield and it can be labeled
with 99mTc and 68Ga in high radiochemical yield and purity. In vitro and in vivo biological
evaluations showed it is feasible to use 99mTc-N4amG in tumor specific imaging.
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CHAPTER 4: 99mTc-GLYCOPEPTIDE(GP) AS A GLUTAMATE TRANSPORTER
TARGETING AGENT FOR PLANAR IMAGING

Portions of this work have been published in Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu CC, Yu D-F, Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and imaging in
breast tumor-bearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.1. Rationale and Study Design
Chitosan is known as a biocompatible polymer with wound healing, anti-infection,
anti- inflammatory and tissue adhesive abilities [80-82]. In order to enhance the cell
membrane penetrating ability and the therapeutic index of chitosan in cancer treatment,
glutamate peptide was conjugated with chitosan. Glutamate is a potent neurotransmitter in
the central nervous system and exerts its action via glutamate transporters [85]. It is also
known that cellular uptake of glutamate peptide is specific to glutamate transporter [86].
Conjugation of glutamate peptide with chitosan resulting GP would be a novel agent to
target tumor vascular and cellular component.

Each synthesized chemical was carefully purified and characterized using NMR,
element analysis and GPC. Since GP has a character of polymer, the capillary
electrophoresis was also used to investigate the purity. In addition, to determine the binding
site of 99mTc in GP, cold Re-glutamate peptide was synthesized. NMR analysis was used to
determine the structure and binding site of Re. The radiochemical purity and stability of
each radiolabeled compounds were tested by radio-HPLC and radio-TLC.

To investigate the pharmacology of 99mTc-GP, a series of in vitro and in vivo studies
using 13762 cells were conducted. In vitro cellular uptake study was conducted to test the
cell penetrating ability of 99mTc-GP. A cellular fraction study and an in vitro blocking study
using glutamic acid as a competitive blocker were conducted to investigate the uptake
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mechanism. Furthermore, in vitro cellular uptake assay pre- and post- paclitaxel treatment
study was performed to demonstrate the ability of using 99mTc-GP in treatment monitoring.

A biodistribution study using 13762 tumor-bearing rats was conducted to evaluate
the exact tumor and organ uptake of 99mTc-GP ex vivo. The distribution of radiotracer in
each organ was expressed as percentage of the injected dose per gram of tissue (%ID/g).
Tumor-to-normal tissue count ratios were determined from the corresponding %ID/g values.
The result of the rat biodistribution study was further used to estimate human radiation
absorption dose by MIRDose 3.1 software.

An in vivo animal imaging study was conducted to investigate the tumor targeting
potential of 99mTc-GP. Tumor-to-muscle count density ratios were determined by dividing
ROI measures (in counts per pixel) of tumor by the measures in a symmetric normal muscle
site. The ratios were used to evaluate the potential of 99mTc-GP in tumor uptake. In addition,
99m

Tc-GP was used to image tumor-bearing rats before and after paclitaxel treatment. This

study was performed to evaluate the treatment monitoring ability of 99mTc-GP. Furthermore,
inflammation and tumor dual-bearing rats were used to investigate the tumor specificity of
99m

Tc-GP. To determine the important pharmacological factor, i.e., biological half-life of

99m

Tc-GP in blood, a blood clearance study was also performed.

In statistical analysis, percent of injected dose per gram of tissue weight (%ID/g) and
tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as mean ± S.D.
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The uptake of 99mTc-GP in different conditions was compared using the Student’s t-test.
Differences were considered to be statistically significant for a two-tailed p<0.05.
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4.2. Results
4.2.1. Chemistry and Radiochemistry
4.2.1.1 Synthesis of Glycopeptide (GP)
Unlike high molecular weight chitosan (MW>100,000), low molecular weight
chitosan (MW 3,500-5,000, 75% deacetylated) is water soluble. Glutamate peptide sodium
salt is water soluble at pH 7.4. GP conjugation was conducted in aqueous solution at pH7.4
using water soluble 3-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl as a coupling
agent. There was no gel formation under this reaction condition. The chemical structure is
shown in Figure 31. Elemental analysis (two times) showed an average C: 41.54; H: 10:62;
N: 7.19 (calculated C: 41.77; H: 8.86; N: 4.43). From elemental analysis data, the estimated
purity of GP was greater than 95% (based upon carbon content). Gel permeation
chromatogram and capillary electrophoresis was used to analyze the purity of GP and the
spectra are shown in Figure 32 and 33. The purities of the starting material chitosan and
glutamate peptide were greater than 95%.
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Figure 31. Structure and the element analysis of GP.
Elemental analysis of GP (C11H14N2Na2O6, C, H, N) showed C: 41.54; H: 10:62; N: 7.19
(calculated C: 41.77; H: 8.86; N: 4.43). The estimated purity of GP was greater than 95%
(based upon carbon content).

117

Figure 32. Gel permeation chromatogram analysis of GP.
The retention time of GP was 9.645 minutes.
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Figure 33. Capillary electrophoresis analysis of GP.
The purity of the starting material chitosan and glutamate peptide were greater than 95%.
Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F,
Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and imaging in breast tumorbearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.1.2. Synthesis of Re-GAP
To determine the binding site of 99mTc in GP, rhenium oxotrichloride (ReOCl3) and
triphenylphosphine were used in the cold Re chemistry.

The estimated NMR (proton and 13C) spectra of position 3-5 in GAP are shown in
left panel of Figure 34 and at the terminal are shown in the middle. The actual NMR spectra
of proton and 13C of Re-GAP are shown in right panel. Our data indicated that Re binds to
GP at the position 3-5 in GAP. The findings suggest that the similar binding site may apply
to 99mTc.
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Figure 34. NMR analysis of cold rhenium-oxo (ReO) (+3) in glutamate peptide.
Compare to estimated spectra data, Re=O was found to bind to the glutamate peptide at the position 3-5. Reprinted with permission
from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F, Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and
imaging in breast tumor-bearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.1.3. Radiolabeling of GP with 99mTc and In Vitro Stability Assays of 99mTc-GP
Radiolabeling of GP with 99mTc was performed in a standard manner [93]. From
radio-TLC (Bioscan, Washington, DC) analysis, the radiochemical purity was more than
95% (Rf = 0.1).

From radio-TLC analysis, the radiochemical purity was more than 95% (Rf = 0.1). In
vitro stability assays indicated there was no breakdown of 99mTc-GP up to 24 hours (Figure
35). A minor breakdown fragment (<4%) was observed at 24 hour. The scale of each
spectrum represents the intensity of radioactivity used. Various 99mTc-GP samples were
detected at the same time and analyzed by radio-TLC at various intervals. The scale
intensity changes due to radioisotope decays. There are variations because radio-TLC
analysis is to analyze radiochemical purity qualitatively.
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Figure 35. In vitro stability assays of 99mTc-GP.
99m

Tc-GP was prepared in the concentration of 10mg/1mCi/1ml. 0.1 mL of 99mTc-GP was
incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 0.5-24 hours. There was no
breakdown of 99mTc-GP up to 24 hours. Reprinted with permission from Wei, I-C, Tsao N,
Huang Y-H, Ho Y-S, Wu C-C, Yu D-F, Yang DJ (2008). 99mTc-glycopeptide: synthesis,
biodistribution and imaging in breast tumor-bearing rodents. Applied Radiation and
Isotopes 66:320-331.
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4.2.2. Pharmacology and Toxicology
4.2.2.1. In Vitro Cellular Uptake Assays
To evaluate whether GP has tumor targeting potential and whether there is a
correlation of uptake as a function of time, an in vitro cellular uptake assay was conducted.
Data are expressed in mean ± S.D. percent of cellular uptake per mg of cell weight from
three measurements. There was a gradually linear uptake of 99mTc-GP in breast tumor cells
suggesting 99mTc-GP has tumor targeting potential (Figure 36).
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Figure 36. In vitro cellular uptake of 99mTc-GP.
Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F,
Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and imaging in breast tumorbearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.2.2. In Vitro Cellular Fraction Assays
To determine the distribution pattern of 99mTc-GP within the cells, NE-PER
extraction reagents were used for stepwise isolation of cytoplasmic and nuclear extracts
from 13762 breast cancer cells. Cytosolic fraction had 60% uptake of 99mTc-GP whereas
nucleus fraction had 40%. Both nucleus and cytosolic fractions in 99mTc-GP were higher
than Na99mTcO4 (Figure 37).
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Figure 37. Cellular fraction assay of 99mTc-GP.
After 2 ml of radioactive media containing 2 µCi (0.074 MBq) of 99mTc-GP (0.02 mg/well)
or sodium pertechnetate (control) was dispensed into each well of a 6-well plate. Cellular
fractions were isolated by centrifugation. Cytosolic fraction had 60% uptake of 99mTc-GP
whereas nucleus fraction had 40%. Both nucleus and cytosolic fractions in 99mTc-GP were
higher than Na99mTcO4. Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho
Y-S, Wu C-C, Yu D-F, Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and
imaging in breast tumor-bearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.2.3. In Vitro Cellular Uptake Assay of 99mTc-GP, Pre- and Post- Treatment
To determine whether 99mTc-GP could monitor post-treatment changes, 13762 rat
breast tumor cells (50,000 per each well) were incubated with paclitaxel (1-5 µM) for 48
hours.

99m

Tc-GP was able to measure uptake differences after cells were treated with

paclitaxel (Figure 38). TUNEL assays revealed that higher doses of paclitaxel induced more
apoptosis (Figure 39). The findings indicated that cellular uptake changes could be
monitored by 99mTc-GP.
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Figure 38. In vitro cellular uptake 99mTc-GP in pre- and post- treatment of paclitaxel.
There was a decreased uptake after paclitaxel treatment (p<0.05). The findings indicate that
99m
Tc-GP was able to measure uptake differences after cells treated with paclitaxel.
Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F,
Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and imaging in breast tumorbearing rodents. Applied Radiation and Isotopes 66:320-331.
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Figure 39. TUNEL assays of breast tumor cells treated with paclitaxel (1-5 µM).
The assays revealed that higher dose of paclitaxel induced more apoptosis. Reprinted with
permission from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F, Yang DJ (2008).
99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-bearing rodents.
Applied Radiation and Isotopes 66:320-331.
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4.2.2.4. In Vitro Cellular Blocking Assay
To determine whether cellular uptake of 99mTc-GP was via a glutamate transporter,
the 13762 rat breast tumor cells were incubated with glutamate (specific) or aspartate
followed by 99mTc-GP. There was decreased uptake in cells treated with glutamic acid but
not with aspartic acid (Figure 40). The results suggested that cellular uptake of 99mTc-GP
was via a glutamate transporter.
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Figure 40. Cellular blocking assay of 99mTc-GP.
There was a dose-dependent decreased uptake in cells treated with glutamic acid, but not
with aspartic acid. The results indicated that cellular uptake of 99mTc-GP was via a
glutamate transporter. Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho YS, Wu C-C, Yu D-F, Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and
imaging in breast tumor-bearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.2.5. Ex Vivo Biodistribution Studies
There was an increased uptake in tumor-to-blood and tumor-to-muscle count density
ratios in breast tumor-bearing rats. The optimum tumor uptake and tumor-to-muscle count
density ratios were 3-5 hours post-administrations. There was no increased uptake in
thyroid and stomach suggesting in vivo stability of 99mTc-GP (Table 9).
excreted through liver and kidneys.
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99m

Tc-GP was

Table 9. Biodistribution of 99mTc-GP in breast tumor-bearing rats.

[Applied Radiation and Isotopes 2008; 66:320-331]
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4.2.2.6. MIRD Dosimetry Estimates
The human residence time estimates were applied to the MIRDose 3.1 software
package to produce radiation dose estimates for 99mTc-GP (Table 10). For 99mTc-GP, the
kidneys and spleen are the primary and secondary contributors, respectively. The MIRD
output was multiplied by a proposed human dose of 20 mCi for
absorbed dose from an imaging study.

99m

Tc-GP to yield total

99m

Tc-GP showed total rad absorbed by each organ

was below the proposed annual and total limits. Based upon preclinical studies, dosimetry
was estimated with MIRDose. Radiation exposure to the whole body, blood-forming organs
(red marrow, spleen), gonads (testes, ovaries), and effective dose equivalent for the
proposed human single dose at 20 mCi fall below the limits of 3 rad annually and 5 rad total.
The absorbed dose in all other organs (e.g., kidneys) was below the limits of single dose of 5
rad annually and 15 rad total. These radiation exposure values are commonly accepted as
criteria for in vivo radiation safety measurement [98].
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Table 10. Radiation dose estimates of the reference adult for 99mTc-GP

[Applied Radiation and Isotopes 2008; 66:320-331]
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4.2.2.7. Scintigraphic Imaging Studies
To demonstrate the application of 99mTc-GP in monitoring treatment response, three
13762 breast tumor-bearing rats were administered with 99mTc-GP (300 μCi/rat, 3 mg
physical amount, iv) at pre- and post-paclitaxel treatment (60 mg/kg, iv, single dose) at 48
hours. In images, the tumors could be well visualized in breast tumor-bearing rats. From
computer outlined region of interest analysis, the average tumor-to-muscle count density
ratios at 0.5 and 1 hour was 3.67±0.60 and 3.85±0.60 (before paclitaxel therapy) and
changed to 2.60±0.61 and 3.20±0.52 (post-paclitaxel therapy).

There was decreased tumor-to-muscle count density ratios (p<0.05 at 1 hour, avg.
17-30%) post-paclitaxel treatment determined by 99mTc-GP at 0.5-1hour. We previously
have reported that the timing of apoptosis occurred at earlier time interval on day 2-3 postpaclitaxel treatment [96] which was supported by histopathology. Though the decrease in
radionuclide retention from tumor-to-muscle count density ratios before and after paclitaxel
treatment is minimal, this might be due to apoptosis that occurred at an earlier time. The
findings from this study indicated that 99mTc-GP is useful in monitoring treatment response
(Figure 41).
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Figure 41. Planar scintigraphy of 99mTc-GP in breast tumor-bearing rats.
Data showed that 99mTc-GP could monitor treatment response. Reprinted with permission
from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F, Yang DJ (2008). 99mTcglycopeptide: synthesis, biodistribution and imaging in breast tumor-bearing rodents.
Applied Radiation and Isotopes 66:320-331.
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4.2.2.8. Scintigraphic Imaging Studies with and without Inflammation
To demonstrate differential diagnosis of 99mTc-GP between tumor and inflammation,
the left legs of 13762 breast tumor-bearing rats were administered with turpentine (0.1 mL,
i.m.). 99mTc-GP had highest tumor and muscle as well as tumor and inflammation count
density ratios compared to 99mTc-chitosan and 99mTc-glutamate peptide (Figure 42). 99mTcGP was able to differentiate tumor and inflammation.
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Figure 42. Planar scintigraphy of 99mTc-chitosan (left two rats), 99mTc-glutamate peptide and
99m
Tc-GP in breast tumor-bearing rats with and without turpentine-induced inflammation.
The data showed that 99mTc-GP had highest tumor and muscle as well as tumor and
inflammation count density ratios compared to 99mTc-chitosan and 99mTc-glutamate peptide.
Reprinted with permission from Wei, I-C, Tsao N, Huang Y-H, Ho Y-S, Wu C-C, Yu D-F,
Yang DJ (2008). 99mTc-glycopeptide: synthesis, biodistribution and imaging in breast tumorbearing rodents. Applied Radiation and Isotopes 66:320-331.
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4.2.2.9. Kinetic Study of Blood Clearance of 99mTc-GP in New Zealand White Rabbit
To determine blood clearance and biological half-life of 99mTc-GP, New Zealand
white rabbits were administered intravenously with 99mTc-GP. The blood clearance of 99mTcGP showed both distribution phase and elimination phase (Figure 43). The elimination
phase was used to calculate the biological half-life (t1/2) of 99mTc-GP. Regression line
formulation (y=-0.0016x+0.2505, R² = 0.952) was estimated using Microsoft Office Excel
2003. The biological t1/2 of 99mTc-GP was 1.30 hr.
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Figure 43. Blood clearance (left panel) and biological half-life analysis of 99mTc-GP.
The biological half-life of 99mTc-GP was 1.30 hours.
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4.3. Discussion
In 99mTc labeling, tin (II) chloride was used to reduce sodium pertechnetate.
However, in rhenium chemistry, the similar condition using tin (II) chloride as reduction
agent was not achievable. In order to label 99mTc, since the amount of sodium pertechnetate
was considered as trace amount, 0.1mg of tin (II) chloride was more than enough to reduce
the entire pertechnetate for labeling. But reduction of cold sodium perrhenate needs more
quantity of tin (II) chloride due to differences in redox potential [120]. Larger amount of tin
(II) chloride in the aqueous solution, however, causes colloidal particles. Besides, the pH
conditions during the reduction are various [120, 121]. Such various pH conditions may not
favorable for GP labeling. It is known that rhenium oxotrichloride (ReOCl3) and
triphenylphosphine (a reducing agent) were the chemicals of choices in cold Re chemistry
[122]. Therefore, rhenium oxotrichloride and triphenylphosphine instead of sodium
perrhenate and tin (II) chloride were adopted to make cold Re-GAP. Our NMR analysis
showed that rhenium bond to glutamate peptide at the position 3-5.

Chitin is the second most abundant natural biopolymer in the world. It is also the
most abundant naturally occurring polysaccharide with amino sugars. Chitosan is derived by
deacetylation of chitin. The difference between chitosan and chitin is the degree of
deacetylation. Chitosan is generally defined as chitin with more than 70% deacetylation rate.
The higher the deacetylation rate, the better physical and chemical properties that chitosan
has. The amino groups make it possible for chitosan to be chemically modified. Chitosan
derivatives are used widely in the pharmaceutical field as drug carriers and excipients. For
instance, intratumoral administration of gadopentetic acid-chitosan complex nanoparticles
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has been used for gadolinium neutron-capture therapy. Chitosan has been applied in drug
delivery [123-125]. It has been reported that chitosan was modified with thioglycolic acid
(TGA) to form chitosan-TGA conjugates. The promising physicochemical properties of
Chitosan-thioglycolic acid conjugates make this chitosan derivative a suitable candidate in
tissue engineering [126]. Despite the various applications of chitosan derivatives, one major
limitation of chitosan is lack of cellular targeting and cellular penetrating abilities.

A previous study has shown that radiolabeled glutamic acid is useful in tumor
cellular imaging [127]. In addition, glutamate peptide has been developed to conjugate with
drug for delivery [128, 129]. To optimize the intracellular uptake of chitosan derivatives,
glutamate peptide was conjugated to chitosan resulting GP copolymer. This copolymer was
first designed as a tumor targeting drug carrier for its amino and/or carboxylic acid groups
are suitable for conjugating with a broad spectrum of anticancer drugs with either amino or
acid groups. GP provides advantages over either chitosan or glutamate peptide along.
Moreover, GP could be easily labeled with radioisotopes, such as 99mTc or 68Ga. This
multifunction biodegradable copolymer is a candidate of imaging guided therapy carrier.

Our in vitro radiolabeling stability assay demonstrated that 99mTc can be stably
labeled with GP for up to 24 hours. We believe it should be attributed to the abundant
carboxylic acids from glutamate peptide, which stabilize 99mTc. Consider another multicarboxylic acid chelator, diethylenetriamine pentaacetic acid (DTPA). DTPA can be labeled
with 99mTc with high radiochemical purity and stability [130]. Several compounds have
been reported to show high 99mTc labeling stability with DTPA as a chelator [93, 131, 132].
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In addition, DTPA can be labeled with other radioisotopes for different imaging modalities.
For instance, 61Cu and 64Cu are used for PET imaging [133], gadolinium for MRI [134,
135], and 188Re for internal radiation therapy [136]. Due to the similar chemical properties
that glutamate peptide and DTPA are shared, GP is an idea material for radioisotopes
labeling.

In the in vitro cellular blocking study, results showed 99mTc-GP could penetrate the
cell membrane and accumulate inside the cell. Inside cells, about 40% uptake 99mTc-GP was
located in the nucleus. In addition, glutamic acid, but not aspartic acid, can specifically
block 99mTc-GP uptake. It indicates GP uptake is through glutamate transporters.

To further investigate whether 99mTc-GP could be used to monitor treatment
response, we used paclitaxel to treat tumor cells for in vitro cell culture studies and in vivo
imaging studies. Our data demonstrated that 99mTc-GP was able to measure uptake
differences after cells treated with paclitaxel in vitro and in vivo. In vitro cell culture results
showed that there was a decrease in cellular uptake of 99mTc-GP. Moreover, from TUNEL
assay, there was an increase in apoptotic cell numbers with increasing concentration of
paclitaxel. Since TUNEL assay is to detect DNA fragmentation by labeling the terminal end
of nucleic acids, TUNEL assay positive cells are considered as apoptotic cells. In vitro cell
culture data implied that the differences between cell uptake before and after paclitaxel
treatment might due to the different numbers of apoptotic cells killed by paclitaxel. In vivo
imaging studies using tumor-bearing rats pre- and post- paclitaxel treatment also showed
that there was a 17-30% decrease in tumor-to-muscle count density ratios after paclitaxel
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treatment. Our previous histopathology finding evidence showed the timing of apoptosis
occurred at earlier time interval on day 2-3 post-paclitaxel treatment [96], 99mTc-GP may be
useful in monitoring tumor apoptosis. Collectively, in vitro and in vivo findings suggested
that 99mTc-GP is useful in monitoring drug-induced apoptosis not only in paclitaxel but also
in other chemotherapy drugs. GP, as a targeted drug carrier, may provide advantages not
only to improve drug solubility but also to overcome drug resistance during chemotherapy.

In the biodistribution study, 99mTc-GP showed high liver and renal uptake. From a
drug metabolism point of view, that might be caused by the metabolic routes of chitosan and
glutamate peptide inside animal body. Chitosan and glutamate peptide were metabolized in
liver and washed out though intestines and kidneys. To overcome the high liver and renal
uptake, 3-dimentional imaging modalities (such as SPECT) or dual imaging modalities
(such as SPECT/CT) would be needed to assess lesions.

In summary, 99mTc-GP can penetrate cell membrane through glutamate transporter.
The in vitro and in vivo data suggested that it is feasible to use 99mTc-GP in tumor
assessment.
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CHAPTER 5:

68

Ga-GP AS A GLUTAMATE TRANSPORTER TARGETING
AGENT FOR PET IMAGING

Portions of this work have been published in Tsao N, Wang C, Her L, Kai Tzen Y, Chen J,
Yu D, Yang DJ (2011). Development of 68Ga-Glycopeptide as an imaging probe for tumor
angiogenesis. Journal of Biomedicine and Biotechnology 2011:267206, doi:
10.1155/2011/267206. PMID:21541212; PMCID: PMC3085313
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5.1. Rational and Study Design
In Chapter 4, I have discussed that GP, a copolymer of chitosan and glutamate
peptide, could target tumor vasculature and cellular through glutamate transporters [92]. In
vitro cellular assays showed that cell uptake of 99mTc-GP was via glutamate transporters.
The biodistribution study revealed increased tumor-to-tissue count ratios as a function of
time. 99mTc-GP could be used to measure tumor uptake changes before and after paclitaxel
treatment. In vitro and in vivo studies confirmed that it is feasible to use 99mTc-GP for tumor
imaging. To evaluate whether GP could also be labeled with 68Ga for PET imaging, the
radiochemical stability, tissue distribution and tumor imaging potential of 68Ga-GP were
studied.

The radiochemical purity and stability of 68Ga-GP was tested by radio-TLC. A
biodistribution study using 13762 tumor-bearing rats was conducted to evaluate the exact
tumor and organ uptake of 68Ga-GP ex vivo. The distribution of radiotracer in each organ
was expressed as percentage of the injected dose per gram of tissue (%ID/g). Tumor-tonormal tissue count ratios were determined from the corresponding %ID/g values. The result
of the rat biodistribution study was further used to estimate human radiation absorption dose
by MIRDose 3.1 software.

In vivo PET imaging studies were conducted in both 13762 tumor-bearing rats and
VX2 tumor-bearing New Zealand white rabbits using 68Ga-GP and 18F-FDG to investigate
the tumor targeting potential of 68Ga-GP. Tumor standardized uptake values (SUVs) and
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dynamic tumor uptakes of both 68Ga-GP and 18F-FDG were calculated. To determine the
important pharmacological factor, i.e., biological half-life of 68Ga-GP in blood, blood
clearance study was also performed.

In statistical analysis, percent of injected dose per gram of tissue weight (%ID/g) and
tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as mean ± S.D.
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5.2. Results
5.2.1. Chemistry and Radiochemistry
5.2.1.1. Radiolabeling of GP with 68Ga and Stability Assay
Radiolabeling of GP with 68Ga was performed in a standard manner [94]. From
radio-TLC (Bioscan, Washington, DC) analysis, the radiochemical purity was more than
95% (Rf = 0.1).

68

Ga-GP was prepared in the concentration of 5mg/1mCi/ml. 0.1mL of 68Ga-GP was

incubated with 0.1mL phosphate buffered saline (pH=7.4) at 37 ºC for 30-120min. In vitro
stability assays indicated that the radiation yield is 98.67% at 30 min and 97.73% at 2 hr
after labeling. There was no breakdown of 68Ga-GP up to 2 hr (Figure 44).

150

Figure 44. In vitro radiochemical stability test of 68Ga-GP.
68

Ga-GP was prepared in the concentration of 5 mg/1 mCi/mL. 0.1 mL of 68Ga-GP was
incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 30-120 minutes. There was no
breakdown of 68Ga-GP up to 120 minutes. Reprinted with permission from Tsao N, Wang C,
Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 68Ga-Glycopeptide as
an imaging probe for tumor angiogenesis. Journal of Biomedicine and Biotechnology
2011:267206, doi: 10.1155/2011/267206. PMID:21541212; PMCID: PMC3085313.
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5.2.2. Pharmacology and Toxicology
5.2.2.1. Biodistribution Studies
There was an increased uptake in tumors (percent of injected dose per gram of
tissue), tumor-to-blood and tumor-to-muscle count density ratios by 68Ga-GP at 0.5-2 hours
whereas the optimum tumor uptake and tumor-to-muscle count density ratios for 18F-FDG
were at 1 hour post-administrations. In biodistribution studies at 30, 60, 120 minutes, tumor
uptake values, tumor/blood and tumor/muscle ratios for 68Ga-GP were 0.68±0.12 to
1.18±0.09, 0.26±0.03 to 0.86±0.09 and 6.12±1.87 to 13.26±4.41; for 18F-FDG were
2.03±0.18 to 2.49±0.08, 5.19±0.38 to 34.37±1.76 and 2.87±0.24 to 7.54±0.56, respectively
(Tables 11 and 12).
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Table 11. Biodistribution of 68Ga-GP in breast tumor-bearing rats

BLOOD

% of injected dose per gram of tissue weight (n=3/time, interval, iv) 1
30 MIN
60 MIN
120 MIN
2.61 ±0.18
1.81 ±0.05
1.37 ±0.05

HEART

0.59 ±0.06

0.43 ±0.02

0.32 ±0.02

LUNG

2.34 ±0.45

2.58 ±0.16

1.38 ±0.06

THYROID

1.10 ±0.11

1.40 ±0.87

0.59 ±0.06

PANCREAS

0.38 ±0.03

0.34 ±0.04

0.28 ±0.02

LIVER

3.81 ±0.32

4.83 ±0.54

4.94 ±0.38

SPLEEN

2.13 ±0.07

2.65 ±0.14

2.97 ±0.11

KIDNEY

1.35 ±0.02

1.36 ±0.01

1.41 ±0.11

STOMACH

0.58 ±0.04

0.65 ±0.07

0.74 ±0.18

INTESTINE

0.54 ±0.12

0.53 ±0.07

0.78 ±0.22

UTERUS

0.70 ±0.02

0.65 ±0.05

0.57 ±0.03

TUMOR

0.68 ±0.12

0.89 ±0.10

1.18 ±0.09

MUSCLE

0.12 ±0.02

0.12 ±0.00

0.10 ±0.02

BONE

0.45 ±0.12

0.46 ±0.09

0.59 ±0.03

BRAIN

0.08 ±0.01

0.07 ±0.01

0.07 ±0.01

TUMOR/BLOOD

0.26 ±0.03

0.49 ±0.07

0.86 ±0.09

TUMOR/MUSCLE

6.12 ±1.87

7.20 ±0.83

13.26 ±4.41

1. Value shown represent the mean  standard deviation of data from 3 animals at (Count at 460-560
keV window)
[Journal of Biomedicine and Biotechnology 2011:267206]

153

Table 12. Biodistribution of 18F-FDG in breast tumor-bearing rats
% of injected dose per gram of tissue weight (n=3/time, interval, i.v.)1
30 MIN

60 MIN

120 MIN

BLOOD

0.40 ±0.04

0.13 ±0.01

0.06 ±0.00

HEART

1.57 ±0.06

1.38 ±0.13

1.08 ±0.07

LUNG

0.55 ±0.06

0.42 ±0.02

0.46 ±0.03

THYROID

1.07 ±0.08

1.04 ±0.04

1.05 ±0.07

PANCREAS

0.26 ±0.03

0.21 ±0.01

0.20 ±0.02

LIVER

0.40 ±0.05

0.16 ±0.01

0.13 ±0.01

SPLEEN

0.82 ±0.08

0.74 ±0.03

0.86 ±0.07

KIDNEY

0.71 ±0.05

0.37 ±0.01

0.24 ±0.02

STOMACH

0.61 ±0.08

0.44 ±0.03

0.39 ±0.03

INTESTINE

0.69 ±0.07

0.53 ±0.03

0.52 ±0.02

UTERUS

0.51 ±0.04

0.42 ±0.03

0.41 ±0.03

TUMOR

2.13 ±0.11

2.49 ±0.08

2.03 ±0.18

MUSCLE

0.33 ±0.04

0.34 ±0.03

0.74 ±0.02

BONE

0.33 ±0.04

0.44 ±0.06

0.50 ±0.03

BRAIN

2.00 ±0.15

1.99 ±0.05

1.39 ±0.09

TUMOR/BLOOD

5.19 ±0.38

19.78 ±1.37

34.37 ±1.76

TUMOR/MUSCLE

5.88 ±0.57

7.54 ±0.56

2.87 ±0.24

1. Value shown represent the mean  standard deviation of data from 3 animals at (Count at 460-560
keV window)
[Journal of Biomedicine and Biotechnology 2011:267206]
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5.2.2.2. MIRD Dosimetry Estimates
The MIRD output was multiplied by a proposed human dose of 20 mCi for 68Ga-GP
to yield total absorbed dose shown in Table 13.

68

Ga-GP showed total rad absorbed by each

organ was below the proposed annual and total limits. Radiation exposure to the whole
body, blood-forming organs (red marrow, spleen), gonads (testes, ovaries), and effective
dose equivalent for the proposed human single dose at 20 mCi fall below the limits of 3 rad
annually and 5 rad total. The absorbed dose in all other organs (e.g., kidneys) was below the
limits of single dose of 5 rad annually and 15 rad total (Table 13). These radiation exposure
values are commonly accepted as criteria for in vivo radiation safety measurement.

155

Table 13. Radiation dose estimates of the reference adult for 68Ga-GP
Radiation Dose Estimates of Reference Adult for 68Ga-GP from Rabbits
ORGANS (5 rem annual/15 rem total)
target organ
adrenals
brain
breasts
gall bladder wall
lli wall
small int
stomach
uli wall
heart wall
kidneys
liver
lungs
muscle
pancreas
bone surfaces
skin
testes
thymus
thyroid
urine bladder wall
uterus
eff dose

rad/mCi
human dose (mCi)
2.54E-04
20
7.37E-06
20
2.78E-04
20
1.03E-04
20
8.24E-06
20
2.34E-05
20
1.69E-04
20
3.02E-05
20
2.30E-04
20
7.92E-05
20
2.13E-04
20
4.62E-04
20
9.27E-05
20
2.54E-04
20
8.54E-05
20
4.65E-05
20
2.09E-06
20
8.81E-04
20
5.34E-05
20
5.92E-06
20
1.11E-05
20
1.48E-04
20

rad
0.005
0.000
0.006
0.002
0.000
0.000
0.003
0.001
0.004
0.002
0.004
0.009
0.002
0.005
0.002
0.001
0.000
0.018
0.001
0.000
0.000
0.003

BLOOD-FORMING ORGANS (3 rem annual/5 rem total)

target organ

rad/mCi

human dose (mCi)

rad

ovaries

1.16E-05

20

0.000

red marrow

1.29E-04

20

0.003

spleen

1.18E-04

20

0.002

eff dose eq

1.60E-03

20

0.032

total body

1.92E-04

20

0.004

[Journal of Biomedicine and Biotechnology 2011:267206]
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5.2.2.3. PET Imaging Studies
Tumors could be well visualized both in breast tumor-bearing rats and VX-2 tumorbearing rabbits (Figures 45 and 46). From PET image ROI analysis, the SUVs for 68Ga-GP
and 18F-FDG in VX-2 tumor-bearing rabbits were 3.25 and 7.04, respectively (Figures 47 and
48). PET images in tumor-bearing rats and rabbits confirmed that 68Ga-GP could assess
tumor uptake. PET dynamic scan showed fast tumor uptake of 68Ga-GP in a New Zealand
white rabbit bearing VX2 tumor (Figure 49). Furthermore, there is no intestine uptake in
68

Ga-GP PET imaging indicated the radioisotope labeling of 68Ga-GP is stable in vivo.
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Figure 45. Dynamic mPET imaging of 68Ga-GP (upper) and 18F-FDG (lower) in breast
tumor bearing rats.
Tumor could be visualized by both compounds. Reprinted with permission from Tsao N,
Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 68GaGlycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and
Biotechnology 2011:267206, doi: 10.1155/2011/267206. PMID:21541212; PMCID:
PMC3085313.
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Figure 46. PET Whole Body imaging at 45 min in New Zealand white rabbits bearing VX2 tumors. (T = tumor)
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang
DJ (2011). Development of 68Ga-Glycopeptide as an imaging probe for tumor angiogenesis.
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.
PMID:21541212; PMCID: PMC3085313.

159

Figure 47. 45 minutes dynamic image with PET-CT of 68Ga-GP in a New Zealand white rabbit bearing VX-2 tumor showed SUV of
the tumor was 3.25.
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 68GaGlycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and Biotechnology 2011:267206, doi:
10.1155/2011/267206. PMID:21541212; PMCID: PMC3085313.
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Figure 48. 45 minutes dynamic image with PET-CT of 18FDG in New Zealand White
Rabbit bearing VX2 tumor showed SUV of the tumor was 7.04.
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang
DJ (2011). Development of 68Ga-Glycopeptide as an imaging probe for tumor angiogenesis.
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.
PMID:21541212; PMCID: PMC3085313.
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Figure 49. 45 Minutes dynamic tumor uptake of 68Ga-GP in a New Zealand white rabbit
bearing VX2 tumor.
The axial view from PET-CT showed the location of tumor. Reprinted with permission from
Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 68GaGlycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and
Biotechnology 2011:267206, doi: 10.1155/2011/267206. PMID:21541212; PMCID:
PMC3085313.
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5.2.2.4. Kinetic Study of Blood Clearance of 68Ga-GP in New Zealand White Rabbit
The blood clearance of 68Ga-GP showed both distribution phase and elimination
phase (Figure 50). The elimination phase was used to calculate the biological half-life of
68

Ga-GP. Regression line formulation (y = -0.0018x + 0.3967, R2 = 0.8375) was estimated

using Microsoft Office Excel 2003. The biological t1/2 of 68Ga-GP was 1.84 hour.
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Figure 50. Blood clearance (left panel) and biological half-life analysis of 68Ga-GP showed
the biological half-life of 68Ga-GP was 1.84 hour.
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang
DJ (2011). Development of 68Ga-Glycopeptide as an imaging probe for tumor angiogenesis.
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.
PMID:21541212; PMCID: PMC3085313.
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5.3. Discussion
In chapter 4, the rationale of GP design was mentioned. GP was designed for tumor
targeting drug carrier purpose. The advantages of GP include: 1. GP is a biodegradable
polymer, which has been proven to be no toxicity in animals even in high dose (data shown
in Chapter 6). 2. GP is a copolymer of chitosan and glutamate peptide. Chitosan derivatives
are used widely in the pharmaceutical field as drug carriers and excipients. Its wound
healing ability and the adhesive property with vascular endothelial cell are reported [137,
138]. 3. The glutamate peptide plays an important role in cellular targeting through
glutamate transporter. Chitosan and glutamate peptide made GP a drug carrier with both
vascular endothelial adhesiveness and cellular targets. 4. GP has abundant amino and
carboxylic acid functional groups which are suitable for conjugating with a broad spectrum
of anticancer drugs with either amino or carboxylic acid functional groups. This property
expends the clinical application of GP-drug conjugates. 5. GP can be easily labeled with
different radioisotopes. In 68Ga-GP radiochemical in vitro stability assay, it showed there
was no breakdown of 68Ga-GP up to 2 hours after labeling. This data along with 99mTc-GP
stability data demonstrated that GP is a stable molecular with proper radioisotope labeling
stabilities.

The molecular weight range of GP was investigated. The optimal molecular weight
range of GP is between 6,000-9,000 Da. With smaller molecular weight (<6,000 Da), GP
may lose its drug delivery capacity and ability. On the other hand, with larger molecular
weight (>9,000 Da), GP may lose its cellular penetrating ability via glutamate transporters
and could also cause toxicity due to the prolonged circulation time. Chitosan, with a
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molecular weight of 3,000-3,500 Da and with deacetylation rate greater than 75%, is
preferred for GP synthesis. A molecular weight larger than 10,000 Da may cause chitosan
insoluble in aqueous solution. Moreover, a lower deacetylation rate will not only affect the
solubility but also provide less drug conjugation capacity. For glutamate peptide,
oligopeptide with ten glutamate units (with molecular weight at 1,500 Da) is preferred. It is
known that a chain of five or more glutamic acids could reduce renal uptake in animal
models [87]. During the reaction, chitosan and glutamate peptide with molar equivalent at
1:2 would be used to synthesize GP.

The biodistribution of 68Ga-GP was similar to 99mTc-GP. Both of them had higher
liver and kidney uptake. It may due to the metabolic path ways of both chitosan and
glutamate peptide. The reason has been discussed in Chapter 4. For the dosimetry data, on
the other hand, 68Ga-GP showed much lower radiation absorption dose (rad) in liver and
kidney than 99mTc-GP. This is because 68Ga has shorter biological half-life and the
biodistribution was conducted only for 2 hours.

In animal imaging studies, we compared 68Ga-GP and 18F-FDG in both 13762 tumorbearing rats and VX2 tumor-bearing rabbit animal models. In microPET imaging study,
because of the large tumor mass, inside the tumor formed a region of necrosis area. 68Ga-GP
only targeted outside living tumor cells but not the inside necrotic region. In VX2 tumorbearing rabbit study, 68Ga-GP showed higher uptake in heart, liver, bone/joint and blood
vessels, and lower uptake in brain and tumor than 18F-FDG. 18F-FDG had higher tumor SUV
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(7.04) compare to 68Ga-GP (3.25). Biodistribution data using 13762 tumor-bearing rats also
confirmed these findings.

The dynamic tumor uptake of 68Ga-GP and 18F-FDG in both rats and rabbit animal
models had very similar results. Both 68Ga-GP and 18F-FDG showed very quick uptake at
the first 1 minute before reached plateau. Both uptakes went up again after 5 minutes ( 68GaGP) and 10 minutes (18F-FDG) in a slower but steady linear manner. This pattern implied a
transporter-based imaging tracer pattern. The first one minute quick plateau reflected the
rapid cell uptake and the saturation of cell membrane transporters (glutamic acid
transporters for 68Ga-GP and glucose transporters for 18F-FDG). After 5 to 10 minutes, the
uptake went up reflected the consumption of these probes as nature nutrition (glutamic acid
for 68Ga-GP and glucose for 18F-FDG). This result implied 68Ga-GP penetrated cell
membrane through glutamate transporter [90, 92].

In summary, at present, there is no angiogenesis imaging agent that targets both
vascular endothelial adhesiveness and cellular transporters. GP interacts with vascular
endothelial and cellular targets. GP also has multiple amino and carboxylic groups, which
allows for anticancer drug conjugates for targeted imaging and therapy. PET imaging studies
indicated that it is feasible to use 68Ga-GP to image tumors. Although 18F-FDG had higher
tumor SUV, 68Ga-GP showed different biodistribution and the ability to differentiae tumor
and necrotic area. In addition, dynamic tumor uptake pattern demonstrated 68Ga-GP
penetrated cell membrane through transporter mechanism. The imaging data obtained from
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68

Ga-GP not only provide an impact on improving the diagnosis of cancer but also provide a

basis for internal radionuclide targeted therapy.
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CHAPTER 6: GP AS A GLUTAMATE TRANSPORTER TARGETING CARRIER
FOR DRUG DELIVERY
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6.1. Rationale and Study Design
GP was designed for tumor targeting drug carrier purpose. In chapters 4 and 5, our
data demonstrated that GP could be labeled with different radioisotopes for imaging and
treatment monitoring. In this chapter, efforts have been make to prove of principle that GPdrug conjugates could target tumor cells, penetrate the cell membrane, prolong tumor
retention time and reduce off-target toxicity, and ultimately, increase anticancer ability.

As a drug carrier, one of the most important characteristics is the safety of the
material itself. GP animal acute toxicity studies were conducted in three different species,
including rat, mouse and rabbit, to investigate the safety range of GP.

To evaluate the tumor targeting abilities of GP-drug conjugates, an in vivo imaging
study using tumor-bearing rat was conducted. Tumor-to-muscle count density ratios were
calculated to test the tumor uptake abilities of each GP-drug conjugate. In addition, a 24
hour imaging after 99mTc-GP-DOX injection was also conducted to investigate the properties
of prolonged circulation and tumor accumulation.

An In vitro cellular viability assay using MDA-MB-231 human breast cell line and
cellular fraction assay using 13762 cells were both conducted to evaluate the cytotoxicity
and intracellular localization of GP-DOX.
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Finally, to prove of principle, an in vivo tumor growth delay study using GP-DOX
and DOX in different doses was performed. The absolute growth delay and tumor growth
curve were calculated to evaluate the efficacy and the toxicity of GP-DOX.

In statistical analysis, the absolute growth delay of DOX and GP-DOX were
compared using the Student’s t-test. Differences were considered to be statistically
significant for a two-tailed p<0.05.
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6.2. Results
6.2.1. Pharmacology and Toxicology
6.2.1.1. Animal Acute Toxicity Studies of GP
Three species (rat, mouse and rabbit) were used to test the acute toxicity of GP.
The rat result: effect of GP on blood chemistry in male and female rats is shown in
Tables 14-17. GP showed no acute toxicity in rats. Dosages up to 400 mg/kg were well
tolerated by rats. The stable compound to be used as an imaging agent in this proposal (10
mg/patient, 70 kg) is considerably (700-2800 times) less than doses tested (100-400 mg/kg)
and shown to have no toxicity in rats.

The mouse result: to ascertain acute toxicity findings in different species, the Swiss
Webster mice (male and female, n=5/gender) were administered GP (1.0 g/kg) and the mice
was observed for 14 days. The body weight was weighed every other day. There was no
marked differences in body weight changes in the mice tested (Figure 51).

The rabbit result: there were no marked adverse effects on blood chemistry were
observed. The blood chemistry data from rabbits is shown in Table 18. The GP compound
to be used as an imaging agent in this proposal (10 mg/patient 70 kg) is considerably (1400
times) less than doses tested in rabbits.
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Table 14. Effect of GP on blood chemistry in female Fischer 344 rats on Day 3.
GP
_
Saline
100mg/kg
200mg/kg
400mg/kg
___________________________________________________________________________
Mean  SD

Mean  SD

Bilirubin (mg/dl)

0.37  0.12

0.20  0.00

0.43  0.15

0.33  0.06

Creatine (mg/dl)

0.39  0.03

0.32  0.02

0.45  0.02

0.39  0.01

Blood Urea
Nitrogen (mg/dl)

17.0  0.26

17.6  0.42

18.8  3.06

18.9  0.29

Glucose (mg/dl)

114  4.0

144  1.0

107  5.0

SGOT (U/L)

134.7  32.6

85.3  18.6

140.0  16.6

93.3  7.9

SGPT (U/L)

61.0  1.00

51.7  1.2

65.3  6.7

53.9  1.2

179  20.5

Total Protein (g/dl) 6.57  0.04
6.18  0.05
7.20  0.14
6.71  0.01
___________________________________________________________________________
Data are expressed as means  SD for 12 rats (3 rats per dose of GP). The rats are
195.0  5g.
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Table 15. Effect of GP on blood chemistry in female Fischer 344 rats on Day 14.
GP
_
Saline
100mg/kg
200mg/kg
400mg/kg
___________________________________________________________________________
Mean  SD

Mean  SD

Bilirubin (mg/dl)

0.37  0.12

0.30  0.00

0.20  0.00

0.20  0.00

Creatine (mg/dl)

0.40  0.02

0.36  0.01

0.35  0.03

0.34  0.02

Blood Urea
Nitrogen (mg/dl)

20.3  0.12

20.9  0.21

22.8  0.21

20.5  1.46

Glucose (mg/dl)

169  25.5

107  0.6

166  13.3

115  1.5

SGOT (U/L)

216.0  46.7

125.3  62.1

88.3  9.5

97.3  25.8

SGPT (U/L)

77.0  1.73

61.0  3.5

57.7  1.5

54.7  0.6

Total Protein (g/dl) 6.49  0.05
6.91  0.04
6.30  0.03
6.44  0.01
___________________________________________________________________________
Data are expressed as means  SD for 12 rats (3 rats per dose of GP). The rats are
195.0  5g.
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Table 16. Effect of GP on blood chemistry in male Fischer 344 rats on Day 3.
GP
Saline
100mg/kg
200mg/kg
400mg/kg
________________________________________________________________________
Bilirubin
0.10.0
0.10.0
0.10. 0
0.10.0
BUN

17.01.2

18.11.1

18.30.9

16.91.5

Creatinine

0.7 0.0

0.7 0.0

0.7 0.0

0.7 0.0

Glucose

1706

1637

1609

1658

SGOT

11012

12111

13015

16140

SGPT

515

535

565

567

Total Protein
6.40.3
6.20.5
6.00.7
6.50.3
__________________________________________________________________
1. Data are expressed as means + S.D. for 12 rats (3 rats per dose).
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Table 17. Effect of GP on blood chemistry in male Fischer 344 rats on Day 14.
GP
Saline
100mg/kg
200mg/kg
400mg/kg
___________________________________________________________________________
Bilirubin
0.10.0
0.10.0
0.10.0
0.10.0
BUN

16.90.9

17.51.3

18.50.9

17.91.2

Creatinine

0.7 0.0

0.7 0.0

0.7 0.0

0.7 0.0

Glucose

1459

14311

15010

14110

SGOT

12911

11210

12015

11013

SGPT
595
526
555
497
Total Protein
6.40.3
6.10.5
6.10.4
6.20.4
___________________________________________________________________
1. Data are expressed as means + S.D. for 12 rats (3 rats per dose).
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Figure 51. GP acute toxicity assay was performed in Swiss Webster mice (males and
females, n=5/gender).
After intravenous injection with GP 1.0 g/kg, body weight changes were monitored for 14
days. The average body weight for male and female was 26 g and 22 g, respectively. The
result shows no significant body weight changes in both male and female mice over 14 days
observation.
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Table 18. Effect of GP on blood chemistry in New Zealand White rabbits (Day 14)
Saline

GP (200mg/kg)

Bilirubin

0.10.0

0.10.0

BUN

18.00.9

22.51.0

Creatinine

0.7 0.0

1.18 0.0

Glucose

1256

1166

SGOT

12310

12012

SGPT

527

545

Total Protein
6.40.6
5.30.3
___________________________________
1. Data are expressed as means + S.D. for 2 rabbits.
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6.2.1.2. Scintigraphic Imaging Studies with GP-drug Conjugates
Four GP-drug conjugates were synthesized, including GP-methotrexate (GP-MTX),
GP-folate (GP-FOL), GP-doxorubicin (GP-DOX) and GP-pamidronate (GP-PAM).
Imaging results demonstrated that GP-drug conjugates accumulated in the tumor (Figure
52).
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Figure 52. Planar scintigraphy of 99mTc-Chi and 99mTc-GP-drug conjugates in breast tumorbearing rats.
Data showed that 99mTc-GP and its conjugates have faster uptake than 99mTc-Chi. The
numbers are tumor to muscle count density ratios (counts/pixel) at 60-180 minutes. MTX:
methotrexate; FOL: folate; DOX: doxorubicin; PAM: pamidronate.
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6.2.1.3. In Vitro Cellular Toxicity Assay (MTT assay)
To determine the cytotoxicity of GP-DOX, an in vitro cellular toxicity assay was
conducted using MDA-MB-231 cells treated with different doses of DOX, GP-DOX and GP
(as a control). As expected, DOX showed a dose dependent cytotoxicity as early as 24
hours after treatment (Figure 53). GP-DOX, on the other hand, showed a mild cytotoxicity
on 24 hours but a strong cytotoxicity on 48 hours. This data indicated that GP-DOX has a
similar cytotoxicity to DOX with slow release pattern.
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Figure 53. Cellular viability assay of GP-DOX.
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6.2.1.4. In Vitro Cellular Fraction Assay
To determine the distribution pattern of 99mTc-GP-DOX within the cells, NE-PER
extraction reagents were used for stepwise isolation of cytoplasmic and nuclear extracts
from breast cancer cells. 20% of intracellular 99mTc-GP-DOX was located in cell nucleus;
whereas 80% was in the cytosol (Figure 54).
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Figure 54. In vitro cellular fraction assay of 99mTc-GP-DOX
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6.2.1.5. Scintigraphic Imaging Studies
To demonstrate the retention of 99mTc-GP-DOX in breast tumor cells, breast tumorbearing rat were administered with 99mTc-GP-DOX (300 µCi/rat, 1.0 mg physical amount,
iv.) Scintigraphic images, using a gamma camera equipped with low-energy, parallel-hole
collimator, were obtained after 2 and 24 hours. Tumor-to-muscle count density ratios
increased from 4.1 at 2 hours to 5.8 at 24 hours (Figure 55). This result indicated that GP
prolonged the circulation time and tumor retention time of DOX.
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Figure 55. 2 and 24 hours planar images of breast tumor-bearing rats with 99mTc-GP-DOX.
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6.2.1.6. In Vivo Tumor Growth Delay Study
Tumor growth delay study was conducted in MDA-MB-231 tumor-bearing nude
mice. Two different doses of DOX (10 mg and 20 mg/kg), four doses of GP-DOX (100 mg600 mg/kg) and normal saline were injected intravenously to animals through tail vain
(single dose). DOX showed high tumor growth delay ability (Figure 56). However, all mice
injected with DOX died on day 11 (DOX: 20 mg/kg) and day 21 (DOX: 10 mg/kg) after
injection suggested the toxicity of DOX (Figure 57). GP-DOX, on the other hand, showed
similar life length to the control animals with similar tumor growth delay ability to DOX
treated animals in the first week after injection. Absolute growth delay was calculated by
using the time (in days) for tumor growth from 70 to 500 mm3 minus the time required for
the control group tumors to reach the same size (70 to 500 mm3) (Figure 58). Three doses of
GP-DOX showed significant growth delay compared to control group (200 mg/kg:
2.11±0.89 days, p<0.024; 300 mg/kg: 3.05±1.28 days, p<0.002; 600 mg/kg: 3.70±1.59 days,
p<0.004). DOX at10 mg/kg also showed significant absolute growth delay as 3.10±2.11
days, p<0.004. Unfortunately, DOX at 20 mg/kg was too toxic and all animals died before
the tumors reached 500 mm3. This result indicated that GP-DOX showed decreased toxicity
with appropriate efficacy.
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Figure 56. Tumor growth delay of GP-DOX and DOX.
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Figure 57. Survival curve of GP-DOX and DOX.
The average survival time was measured by calculating the lifetime of mice (until death)
after different treatments. Mice in the GP-DOX600-0.4 group showed a longer average
survival time than those in the other groups.
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Figure 58. Absolute growth delay of GP-DOX and DOX.
Absolute tumor growth delay (aGD) under treatment with DOX alone and GP-DOX
compared with treatment for tumors with mean ± S.D. A more than additive treatment effect
was observed in GP-DOX.
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6.3. Discussion
In the GP acute toxicity assay, all three tested animal species showed no significant
changes in blood chemistry or body weight compared to control group. In rat, the injection
doses were 100 mg, 200 mg and 400 mg/kg single dose intravenous injection. Considering
the practical human dose (10 mg/human, 70kg), these doses were 700-2,800 times higher
than human dose (based on weight-to-weight calculation). In rabbit, 200 mg/kg of GP was
injected. this was 1,400 times higher than the human dose. The acute toxicity results
demonstrate that GP is a safe material for injection. In mouse, body weight, instead of blood
chemistry, was measured and recorded to evaluate the safety of GP. There was no
significant body weight (15%) change after two weeks of injection.

The in vivo imaging study of 99mTc-labeled GP-drug conjugates showed that all
testing GP-drug conjugates accumulated in tumor and the accumulations were increased by
time. The highest tumor-to-muscle density count ratio was for 99mTc-GP followed by 99mTcGP-MTX and 99mTc-GP-FOL. All testing compounds showed tumor-to-muscle ratio greater
than 3.5 (at 3 hour imaging). However, the biodistribution of each testing compound was
slightly different, which reflected the different chemical and physiological properties of each
GP-drug. For instance, 99mTc-GP-PAM showed low liver uptake but high bone uptake. Since
pamidronate itself is a bone seeking agent, conjugation with GP preserved part of its original
property. Furthermore, in the prolonged imaging study (24 hours after injection),

99m

Tc-GP-

DOX showed prolonged retention in tumor (tumor-to-muscle ratio reached 5.8; 4.1 at 2
hours). This data indicated that GP can not only bring drugs to target tumor, but it can also
help drugs remain in the tumor.
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The in vitro cellular viability assay demonstrated another important ability of GP in
polymeric drug delivery. The data showed that at the same DOX equivalent concentration,
GP-DOX killed cells almost as much as DOX at 48 hour but not 24 hours. At 24 hours, GPDOX only showed half to one-third cytotoxicity. This data indicated that GP-DOX
demonstrated a slow-release pattern in cell culture media. In addition, from the in vitro
cellular fraction assay, about 20% of 99mTc-GP-DOX located inside the cell nucleus,
whereas 80% of 99mTc-GP-DOX was in cytosol. In the similar cellular fraction study, we
found 99mTc-GP located 40% in cell nucleus and 60% in cytosol. This difference confirmed
our earlier observation that GP-drug conjugation changed the properties of both GP and
drugs.

To evaluate the efficacy of GP-DOX, an in vivo tumor growth delay study was
conducted. This assay measured the response of tumor to drug treatment in vivo. The
absolute growth day data showed GP-DOX at 200 mg/kg had 2 days of absolute growth
delay. Moreover, GP-DOX at 300 mg and 600 mg/kg showed similar absolute growth delay
(3 days and 3.7 days in average, respectively) with DOX at 10 mg and 20 mg/kg (3 days). In
the tumor growth delay studies, although 10 mg and 20 mg/kg of DOX injection showed
greatest tumor growth delay, testing animals died in the middle of the study (day 63 and day
56, respective). On the other hand, GP-DOX at 300 mg and 600 mg/kg showed slow tumor
growth with testing animals remaining alive until day 65 (end of study). This result
demonstrated the efficacy and low toxicity of GP-DOX.
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To prove the principle that GP can be used for drug conjugation, methotrexate, folate,
doxorubicin and pamidronate were conjugated with GP. The conjugation rates were above
28.7% (w/w) measured by UV spectroscopy method. GP-DOX was selected for the in vitro
and in vivo evaluation for the highest conjugation rate (33.5%, w/w) and the broad
applications in cancer treatment. Doxorubicin is used in the treatment of cancers such as
acute leukemia, lymphomas, breast carcinoma, sarcomas, bronchogenic (lung) carcinoma
[139-141]. However, limited solubility and target non-selectivity of DOX leads to damage
of healthy tissues, with particularly severe injury in myocardial tissue [142]. In other words,
DOX may cause cardiotoxicity in a dose-dependent manner, which is the major drawback
and limiting factor for its application [143]. By conjugating with GP, the solubility of DOX
is highly increased. In addition, GP increases tumor uptake of DOX; hence, the target nonselectivity of DOX is also reduced. Furthermore, the slow release pattern and longer tumor
retention time both increases the therapeutic index of DOX, and potentially, decreases the
cardiotoxicity.

In summary, in vitro and in vivo data along with imaging findings indicate that GP is
a potential theranostic carrier with active and passive tumor targeting abilities, circulation
time increasing ability and slow release ability.
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CHAPTER 7: SUMMARY, SIGNIFICANCE AND FUTURE DIRECTIONS
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7.1. Summary
The purpose of this study was to design, synthesize and develop novel transporter
targeting agents for image-guided therapy and drug delivery. Two agents, N4amG and GP,
were synthesized for nucleoside transporter and amino acid transporter targeting,
respectively. We hypothesized that radiolabeled N4amG and GP can actively penetrate the
cell membrane through transporters. Furthermore, the retention of radiolabeled N4amG and
GP in tumors will allow specific assessment of tumors. Lastly, I proposed that GP-DOX
conjugates will be more specific and less toxic than DOX in tumor treatment. Therefore, in
the first specific aim, N4amG and GP were synthesized and radiolabeled with 99mTc and
68

Ga. The chemical and radiochemical purities as well as radiochemical stabilities of

radiolabeled N4amG and GP were tested. In vitro stability results showed both 99mTcN4amG and 99mTc-GP are stable up to 6 hours, whereas 68Ga-GP is stable at least 2 hours. In
vitro cell culture studies from Specific Aim 2 then confirmed radiolabeled N4amG and GP
can penetrate the cell membrane through nucleoside transporters and amino acid
transporters, respectively. Up to 40% of intracellular 99mTc-N4amG and 99mTc-GP locate in
cell nucleus after 2 hours incubation. Cell sorting assay revealed 99mTc-N4amG is a cell
cycle S phase-specific agent. The uptake of 99mTc-GP in pre- and post- paclitaxel treated
cells showed significant differences, which demonstrated the ability of 99mTc-GP in
chemotherapy treatment monitoring. In Specific Aim 3, radiolabeled N4amG and GP were
tested in vivo using tumor-bearing animal models. 99mTc-N4amG showed tumor-to-muscle
ratios up to 5 at 4 hour imaging. Both 99mTc-labeled agents showed decreased uptake after
paclitaxel treatment. IHC results demonstrated that the uptake of 99mTc-N4amG is correlated
to Ki-67 staining. In tumor/inflammation dual-bearing animal studies, both 99mTc-N4amG
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and 99mTc-GP showed differentiation between tumor and inflammation. In addition, 68Ga-GP
was compared to 18F-FDG in rabbit PET imaging studies. Although 68Ga-GP had lower
tumor SUV, 68Ga-GP showed different biodistribution and similar tumor uptake dynamics to
18

F-FDG. Finally, for a proof of concept that GP can be a potential drug carrier for cancer

theranostics, selected drugs were conjugated to GP. Imaging studies demonstrated that GPdrug conjugates increased tumor uptake as a function of time. GP-DOX showed a slowrelease pattern in the in vitro cytotoxicity assay and showed anti-cancer efficacy with
reduced toxicity in the in vivo tumor growth delay study. Collectively, these data reveal that
N4amG and GP are both transporter targeting agents. Radiolabeled N4amG can be used for
tumor cell proliferation assessment. GP is a potential technology platform for image-guided
therapy and drug delivery.
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7.2. A Novel Nucleoside-based Functional Radiotracer
Nucleoside analogs have long been an attractive source for imaging probe designing.
Many radiolabeled nucleoside analogs have been reported. Most of those radiolabeled
purine and pyrimidine were probes for imaging reporter gene expression, especially for
herpes simplex virus type 1 thymidine kinase (HSV1-tk) expression. For instance,
pyrimidine derivatives: 2'-fluoro-2'-deoxy-5-iodo-1-ß-D-ribofuranosyl-uracil (FIRU), 2'fluoro-2'-deoxy-5-iodo-1-ß-D-arabinofuranosyluracil (FIAU), 2'-fluoro-2'-5-methyl-1-ß-Darabinofuranosyluracil (FMAU), 2'-fluoro-2'-deoxy-5-iodovinyl-1-ß-D-ribofuranosyl-uracil
(IVFRU), and acycloguanosine derivatives: 9-[4-hydroxy-3-(hydroxy-methyl)butyl]guanine
(PCV), 9-[(2-hydroxy-1-(hydroxymethyl) ethoxy)methyl]guanine (GCV) [144-149], and
other 18F-labeled acycloguanosine derivatives: 8-fluoro-9-[4-hydroxy-3 (hydroxymethyl)
butyl]guanine (FPCV) [146, 147] , 8-fluoro-9-[(2-hydroxy-1(hydroxymethyl)ethoxy)methyl]guanine (FGCV) [144, 148], 9-[4-fluoro-3(hydroxymethyl)butyl]guanine (FHBG) [150, 151], 9-[3-fluoro-1-hydroxy-2propoxymethyl]guanine (FHPG) [152, 153] have all been developed as probes for imaging
wild-type and mutant [146] HSV1-tk expression. The reason for targeting HSV1-tk is
mainly for reporter gene expression assessment. This reporter gene imaging technology may
be used in the future for transgene therapy monitoring and assessment. However, the utility
of using reporter gene imaging depends mostly on the delivery method of the reporter gene
in vivo. Each delivery method, namely adenoviral vector, liposome and direct injection, has
its own limits. Therefore, the application of using radiolabeled purine or pyrimidine for
HSV1-tk imaging is limited. Not to mention that the radiolabeled purine or pyrimidine used
for HSV1-tk imaging is basically imaging reporter gene expression not imaging cell
197

proliferation. Other radiolabeled nucleoside analogs which are used for cell proliferation
assessment, such as 11C-thymidine, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-[methyl11

C]thymine (11C-FMAU), deoxyuridine (UdR; I, Br or F labeled) and 18F-FLT, have their

own limitations. 11C-labeled compounds lack of clinical application due to short radioactive
half-life (20.3 minutes). In addition, 11C-thymidine can be metabolized in human body very
rapidly. 124I-, 76Br- or 18F-labeled UdR suffers from the rapid dehalogenation in vivo [154].
As for 18F-FLT, as mentioned in Chapter 1, low DNA incorporation and complex chemistry
with poor yield limit its application. All in all, although many radiolabeled nucleoside
analogs have been developed for imaging, no agent has yet been approval for clinical use in
patients.

Our data demonstrated that N4amG has certain characteristics beyond current
nucleoside-based radiotracers for imaging cell proliferation. First, N4amG resists cellular
nucleoside metabolism. N4amG is a derivative of guanosine, which is one of the essential
nucleosides for both DNA and RNA. Different from guanosine, however, N4amG has a
carbon chain instead of a deoxyribose. Similar to penciclovir metabolism [54], this carbon
chain makes N4amG structurally similar to guanine, but resistant to purine nucleoside
phosphorylase (PNP), which metabolizes guanosine to guanine. The PNP resistance
increases the chance of N4amG being phosphorylated and, as a result, increases the DNA
incorporation. Secondly, cold N4amG drug substance can be synthesized in large amounts
with an appropriate yield. The radiochemical yield and radiochemical purity of 99mTcN4amG and 68Ga-N4amG are both greater than 95%. The high radiochemical yield and
purity should be attributed to chelation chemistry, which has been mentioned in Chapter 1.
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Another advantage of using chelation chemistry is the capacity of labeling with different
radioisotopes for different purposes in single cold agent, in this case, N4amG. Labeling
ability of 99mTc and 68Ga has been tested in this study for imaging purposes. Other
radioisotopes, such as 188Re, 177Lu and 90Y are potential candidates to label with N4amG for
radiation therapy purposes. Furthermore, N4amG has the potential to be produced, delivered
and stored as a cold kit product. Before usage, N4amG can then be labeled with desired
radioisotopes produced onsite from in-house generators. Moreover, our in vitro results
revealed the high cellular uptake, nucleus-directed, cell cycle S phase-preferred properties of
radiolabeled N4amG. Finally, from imaging results, both tumor-to-muscle ratio and tumorto-inflammation ratio indicated the tumor specificity of 99mTc-N4amG.

The logical next step of this project will be in two directions: the improvement of
N4amG chemistry and the more detailed study of N4amG uptake and accumulation
mechanisms. From a medicinal chemistry point of view, the amide linkage (peptide bond)
between bifunctional chelator (N4) and lead compound (penciclovir) is relatively fragile. It
is stronger than an ester linkage, which could be rapidly hydrolyzed by esterase in vivo, but
it still can be hydrolyzed by protease, such as trypsin. An amide linkage is suitable for
diagnostic agents because of its relatively faster elimination time in vivo, which will reduce
the radiation absorption dose for patient and will increase imaging quality by reducing the
background noise in the image. For therapeutic usage, a carbon-nitrogen bond is preferred
because it gives resistance to proteases resulting in longer circulation time. Attempts have
been made to synthesize N4-Guan and EC-Guan with carbon-nitrogen bond between
chelators and lead compound. Unfortunately, low to zero overall yield made these attempts
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fail. I have discussed possible reasons of the failure in Chapter 3; here, I want to focus on
the solution. One of the possible reasons of the failure is the bulky protection group blocks
the space causing unfavorable SN2 reaction condition. A possible solution is to exchange the
bulky methoxytrityl group with a smaller protection group, such as BOC-group. By reducing
the spatial barrier, it could possibly increase the yield.

With reference to N4amG uptake mechanism, although we have shown the uptake of
99m

Tc-N4-Guan is through NTs, which one of hNTs is responsible for the uptake becomes

the next question. hNT protein families have been discussed in Chapter 3. First of all, the
expression of hNTs in the testing cell lines should be determined. Since there are no
commercially available antibodies to detect hNTs, real-time PCR is the best way to analyze
the hNTs expression in cell. Primers and probes of hNTs as listed in Table 19 are acquired
from known literature [36]. To determine which hNTs is/are responsible 99mTc-N4amG
uptake, an inhibition study can be performed using hNT specific inhibitors with Na+-positive
buffer and Na+-negative buffer. This design is based on the fact that hENTs are sodiumindependent and hCNTs are sodium-dependent. Furthermore, the intracellular 99mTc-N4amG
needs to be further phosphorylated to become nucleotide analogue (triphosphate) in order to
involve in DNA/RNA synthesis. Unphosphorylated 99mTc-N4amG could be transported out
of cells through the same transporter system. Phosphorylation of penciclovir by a cellular
deoxyguanosine kinase has been reported [54]. It is very crucial to understand whether the
same cellular enzyme can phosphorylate 99mTc-N4amG in vivo, and thus, it helps radiotracer
accumulate in the cells. Furthermore, only single cell line (13762, rat breast adenocarcinoma
cell) was used in both in vitro and in vivo studies. Although 99mTc-N4amG showed high
200

cellular uptake and tumor-to-muscle count density ratios in our testing models, it may just be
a cell type-specific phenomenon. It is necessary to use a second and/or a third cell line to
confirm the findings. A549 cells can be used in future study because it is one of the few cell
lines that express almost all hNTs, including hCNT2, which is known to have the capacity in
transporting purines in vivo. In addition, A549 cell line was derived from a lung carcinoma,
and 18F-FLT-PET has been reported to have high potential utility in lung cancers [155].
Moreover, MCF-7, U251 and Capan-2 cells (derived from a breast adenocarcinoma,
glioblastoma and pancreatic carcinoma, respectively) are potential candidates because these
cell lines express high level of hNTs [36].
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Table 19. Real-time PCR probe and primer concentrations and sequences.
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7.3. A Novel Polymeric Drug Delivery Platform for Cancer Theranostics
Despite the fact that hundreds of drugs have been proved to kill cancer cells, cancer
still remains the population’s greatest health fear. One of the main reasons is cancer’s nature
of heterogeneity and adaptation. A single agent can only kill a part of cancer for a certain
amount of time. To overcome this therapeutic limitation, it is necessary to develop a
technology platform with the abilities to predict cancer treatment plan, deliver appropriate
drug(s) to the right site, monitor treatment response and conjugate to as many as different
drugs. From this point of view, a polymeric (multi-) drug delivery system with imaging
capacity is one of a few qualified technology candidates.

Theoretically, cancer theranostics using polymeric drug delivery technology
approach seems promising. Practically, however, there are many barriers from the laboratory
bench to the patient’s bedside. In order to be used in humans, certain issues of the polymeric
carrier itself need to be first clarified. These issues include toxicity, biocompatibility,
elimination routes, clearance rate (biological half-life), off-target distribution,
pharmacokinetics and targeting efficiency [62].

GP was typically designed for polymeric cancer theranostic approach. This study
investigated and revealed chemical and physiological properties of GP for clinical use.
Multi-carboxylic and amino functional groups not only help GP to stably chelate
radioisotopes for imaging, but they also provide wild range of anti-cancer drug conjugation.
The combination of chitosan and glutamate peptide brings GP both abilities to target tumor
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angiogenesis and penetrate tumor cell membrane through glutamate transporter. Drugs are
given the similar tumor targeting ability by conjugating with GP. The safely and
biocompatibility of GP extends its clinical application.

In cancer theranostic technology development, another barrier that bothers scientists
is the different dosage requirements for both diagnostic and therapeutic properties of these
agents. As McCarthy pointed out in a theranostic nanoparticles study based on coencapsulating of 18F and DOX [156], since the usual working dose for 18F imaging is about
0.5–1.0 μg/kg body weight whereas for DOX is about 2 mg/kg, it is highly possible that the
patient receives an excess of maximum allowable 18F exposure with not enough DOX
therapeutic dose. Unlike nanoparticles, GP overcomes this problem simply by using
different physical amounts in imaging and in therapy. Moreover, our data demonstrated GPdrug conjugates can be labeled with 99mTc for imaging.

The development of hybrid multimodality imaging technology is in progress.
SPECT/CT and PET/CT are currently available. Even SPECT/MR and PET/MR are under
development as they provide functional and anatomical information with less ionizing
radiation [4]. Therefore, polymeric cancer theranostic technologies carrying multiple
imaging probes, including the combination of PET, fluorescent and MRI probes for
multimodality imaging are being developed [62, 157]. GP can be labeled with both 99mTc
and 68Ga for SPECT and PET imaging, respectively. Our preliminary results using
gadolinium-ethylenediaminetetraacetic acid conjugated chitosan (Gd-EDTA-chitosan)
showed increased tumor visibility in pig MR imaging. To evaluate the possible toxicity of
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Gd and to expend the future application, more evaluation on Gd-EDTA-chitosan regarding
safety and efficacy are in progress.

Based on the facts that chitosan shows high affinity to the vascular endothelial cells
and glutamate peptide can penetrate cell membranes, radiolabeled GP can be a potential
imaging probe for tumor angiogenesis [90, 92]. Tumor angiogenesis not only provide
nutrient and oxygen support for tumor growth, but also facilitate tumor metastasis. The
vascular density, in certain tumors, can be used as a prognostic indicator for metastatic
potential. In other words, a tumor with higher vascular density has a higher chance of
metastasis [158]. Measurement of angiogenesis in solid tumors can be used as a biomarker
for tumor progression, metastasis and prognosis [159, 160]. Since there is no angiogenesis
imaging agent focused on both vascular endothelial adhesiveness and cellular target,
radiolabeled GP has the potential to access tumor angiogenesis through a dynamic, noninvasive way. As a result, GP images may become a useful tool for the assessment of tumor
progression, metastasis and prognosis.

The Enhanced Permeability and Retention (EPR) effect is known as one of the
mechanisms for macromolecular drugs to target solid tumors. It was first reported in 1986
[161]. To ensure a sufficient supply of oxygen and nutrients for rapid growth, most solid
tumors produce large amounts of various vascular permeability factors and have defective
blood vessels. As a result, most solid tumors exhibit enhanced vascular permeability [162164]. The unique defective architecture nature of tumor blood vessels facilitates
macromolecules transport into tumor tissues. The EPR effect is a molecular weight205

dependent phenomenon. It has been reported that the EPR effect benefits macromolecules
with molecular weights large than 40 kDa to accumulate in tumor tissues [165]. The
molecular weight of GP was 6,000-9,000 Da. Therefore, the tumor targeting ability of GP
may not directly caused by the EPR effect. GP was designed for cancer theranostic
purposes. Macromolecules (>40 kDa) may not suitable for nuclear imaging due to the slow
blood clearance rate and the high background noise in the image. As discussed in section
5.3., the optimal molecular weight range (6,000-9,000 Da) facilitated GP for both tumor
vascular and intracellular targeting.

Kit formation is one of the advantages of chelation chemistry-based radiotracers.
Many clinically used 99mTc-labeled radiotracers are commercially available in single kit
form. The formulation of each kit was approved by FDA and listed on the United States
Pharmacopeia (USP). Take DTPA kit (Jubilant DraxImage Inc., Quebec, Canada) as an
example, 99mTc-DTPA is usually used in clinic for renography. The chemical ingredients in
a single kit include DTPA 20 mg, p-aminobenzoic acid 5 mg, calcium chloride dihydrate
3.73 mg and stannous chloride dihydrate 0.25mg. The cold kit should be stored at 2 ℃ to 25
℃. To prepare 99mTc-DTPA for injection, up to 500 mCi of 99mTc is added to the vial
through a syringe. After 15 minutes, 99mTc-DTPA is ready to use for the next 12 hours.
Several efforts have been made to produce GP single kit. Stannous chloride is one of the
essential ingredients, which is responsible for pertechnetate reduction. Anti-oxidant agents
such as ascorbic acid are considered to keep the reduction ability of stannous chloride. Other
agents may also add to the formula for various purposes including osmolarity maintenance
and image improvement. During the preparation of kit solution, the pH value and oxygen
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content are important and need to be well controlled. A continuous nitrogen gas bubbling is
highly recommended. After filter the solution through a 0.22 µm sterile filter, solution is
dispensed in the vials and ready for lyophilization. The water content and storage
temperature are also crucial for stabilizing kit product. As a future direction, there is still
room for improvement of GP kit formulation.
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7.4 . Conclusion
In conclusion, the present study has discovered and developed two novel agents,
N4amG and GP. Due to the need of cell proliferation imaging tracer and theranostic
technology platform, both agents appear extremely promising. Radiolabeled N4amG has the
potential to target proliferating cells; as a result, it can better differentiate between
proliferating cells from resting, necrotic or apoptotic cells, as well as tumor from
inflammation. In clinical application, N4amG has the potential to monitor treatment
response and to detect tumor with higher accuracy. Furthermore, the convenient
radiolabeling chemistry and cost-effectiveness make N4amG more accessible to a wide
range of patients. Radiolabeled GP shares similar radiochemical convenience and costeffectiveness due to chelation chemistry and less expensive radioisotopes. Our data
indicated GP has the ability to target tumor in vitro and in vivo. By conjugating GP with
anticancer drugs, great benefits will be achieved including longer circulation time, less offtarget effect, slow release pattern and better solubility. In other words, GP can increase the
therapeutic index of cancer chemotherapy drugs. In clinical application, radiolabeled GP
may be used for treatment planning. With high tumor uptake of GP, patients may then be
treated with GP-drugs. Treatment responses can be evaluated by either radiolabeled GP or
N4amG.
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